utahmedical.htm

0001096906-15-000860.txt : 20150807 0001096906-15-000860.hdr.sgml : 20150807 20150807164149 ACCESSION NUMBER: 0001096906-15-000860 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150807 DATE AS OF CHANGE: 20150807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 151038063 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 10-Q 1 utahmedical.htm UTAH MEDICAL PRODUCTS, INC.10Q 2015-06-30 utahmedical.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Quarterly Report Under Section 13 or 15(d) of

The Securities Exchange Act of 1934

For quarter ended: June 30, 2015

Commission File No. 001-12575

UTAH MEDICAL PRODUCTS, INC.

(Exact name of Registrant as specified in its charter)

UTAH	87-0342734
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

7043 South 300 West

Midvale, Utah 84047

Address of principal executive offices

Registrant's telephone number:

(801) 566-1200

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and; (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Accelerated filer x

Non-accelerated filer o

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of August 6, 2015: 3,758,300.

UTAH MEDICAL PRODUCTS, INC.

INDEX TO FORM 10-Q

PART I - FINANCIAL INFORMATION			PAGE

	Item 1.	Financial Statements

		Consolidated Condensed Balance Sheets as of June 30, 2015 and December 31, 2014	1

		Consolidated Condensed Statements of Income for the three and six months ended June 30, 2015 and June 30, 2014	2

		Consolidated Condensed Statements of Cash Flows for the six months ended June 30, 2015 and June 30, 2014	3

		Notes to Consolidated Condensed Financial Statements	4

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	6

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	15

	Item 4.	Controls and Procedures	15


PART II – OTHER INFORMATION

	Item 1.	Legal Proceedings	16

	Item 1A.	Risk Factors	16

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18

	Item 6.	Exhibits	19

SIGNATURES			19

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
JUNE 30, 2015 AND DECEMBER 31, 2014
(in thousands)
	(unaudited)			(audited)
ASSETS	JUNE 30, 2015			DECEMBER 31, 2014
Current assets:
Cash	$	19,169		$	19,274
Investments, available-for-sale		59			58
Accounts & other receivables, net		5,613			4,703
Inventories		4,473			4,872
Other current assets		662			768
Total current assets		29,976			29,675
Property and equipment, net		7,746			8,236
Goodwill		15,216			15,145
Other intangible assets		40,015			39,675
Other intangible assets - accumulated amortization		(13,023	)		(11,655	)
Other intangible assets, net		26,992			28,020
Total assets	$	79,930		$	81,076

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	932		$	929
Accrued expenses		4,401			4,148
Current portion of notes payable		-			3,894
Total current liabilities		5,333			8,971
Notes payable		-			973
Deferred tax liability - intangible assets		5,370			5,581
Deferred income taxes		1,034			995
Total liabilities		11,737			16,520

Stockholders' equity:
Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding		-			-
Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2015, 3,757 shares and December 31, 2014, 3,748 shares		38			37
Accumulated other comprehensive income (loss)		(3,408	)		(3,234	)
Additional paid-in capital		3,029			2,890
Retained earnings		68,534			64,863
Total stockholders' equity		68,193			64,556

Total liabilities and stockholders' equity	$	79,930		$	81,076

see notes to consolidated condensed financial statements

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
THREE AND SIX MONTHS ENDED JUNE 30, 2015 AND JUNE 30, 2014
(in thousands, except per share amounts - unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2015			2014			2015			2014
Sales, net	$	10,397		$	10,491		$	20,630		$	20,318

Cost of goods sold		4,298			4,142			8,419			7,919

Gross profit		6,099			6,349			12,211			12,399

Operating expense

Selling, general and administrative		1,992			2,172			4,071			4,256
Research & development		140			115			296			238

Total operating expenses		2,132			2,287			4,367			4,494

Operating income		3,967			4,062			7,844			7,905

Other income (expense)		(43	)		(132	)		(252	)		(193	)

Income before provision for income taxes		3,924			3,930			7,592			7,712

Provision for income taxes		1,006			1,096			2,006			2,156

Net income	$	2,918		$	2,834		$	5,586		$	5,556

Earnings per common share (basic)	$	0.78		$	0.76		$	1.49		$	1.48

Earnings per common share (diluted)	$	0.77		$	0.75		$	1.48		$	1.47

Shares outstanding - basic		3,755			3,750			3,753			3,750

Shares outstanding - diluted		3,773			3,775			3,775			3,778
Other comprehensive income (loss):
Foreign currency translation net of taxes of $0 in all periods	$	2,360		$	859		$	(175	)	$	1,110
Unrealized gain (loss) on investments net of taxes of $2, ($0), $0 and ($2)		2			(0	)		1			(3	)
Total comprehensive income	$	5,280		$	3,693		$	5,412		$	6,663

see notes to consolidated condensed financial statements

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2015 AND JUNE 30, 2014
(in thousands - unaudited)

	Six Months Ended June 30,
	2015			2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	5,586		$	5,556
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation		301			311
Amortization		1,259			1,376
(Gain) loss on investments		-			-
Provision for (recovery of) losses on accounts receivable		(9	)		6
(Gain) loss on disposal of assets		1			4
Deferred income taxes		(213	)		(282	)
Stock-based compensation expense		44			24
Changes in operating assets and liabilities:
Accounts receivable		(828	)		(1,016	)
Accrued interest and other receivables		(81	)		(31	)
Inventories		218			(472	)
Prepaid expenses and other current assets		104			118
Accounts payable		5			91
Accrued expenses		(654	)		75
Total adjustments		147			204
Net cash provided by operating activities		5,733			5,760

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
Property and equipment		(109	)		(836	)
Intangible assets		(7	)		-
Net cash provided by (used in) investing activities		(116	)		(836	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options		245			271
Common stock purchased and retired		(215	)		(818	)
Payment of taxes for exchange of stock options		(42	)		-
Tax benefit attributable to exercise of stock options		107			120
Repayment of notes payable		(4,778	)		(2,035	)
Payment of dividends		(957	)		(938	)
Net cash provided by (used in) financing activities		(5,640	)		(3,400	)

Effect of exchange rate changes on cash		(82	)		20

Net increase (decrease) in cash and cash equivalents		(105	)		1,544

Cash at beginning of period		19,274			14,395

Cash at end of period	$	19,169		$	15,939

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for income taxes	$	2,781		$	1,551
Cash paid during the period for interest		65			167

see notes to consolidated condensed financial statements

UTAH MEDICAL PRODUCTS, INC.

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(unaudited)

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2014. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

(2) Recent Accounting Standards. In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

(3) Inventories at June 30, 2015 and December 31, 2014 consisted of the following:

	June 30,		December 31,
	2015		2014
Finished goods	$	1,554	$	1,847
Work-in-process		1,101		1,103
Raw materials		1,818		1,922
Total	$	4,473	$	4,872

(4) Stock-Based Compensation. At June 30, 2015, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended June 30, 2015 and 2014, the Company recognized $22 and $18, respectively, in stock based compensation cost. In the six months ended June 30, 2015 and 2014, the Company recognized $44 and $24, respectively, in stock based compensation cost.

(5) Notes Payable. In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. and a $12,934 loan from JP Morgan Chase, London Branch to help finance UTMD’s purchase of Femcare. The notes were fully paid off in February 2015.

(6) Warranty Reserve. The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.”

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2014 or June 30, 2015.

(7) Investments. Changes in the unrealized holding gain/loss on investment securities available-for-sale and reported as a separate component of accumulated other comprehensive income are as follows:

		2Q 2015		2Q 2014
Balance, beginning of period	$	8	$	5
Realized loss from securities included in beginning balance		-		-
Gross unrealized holding gains (losses), in equity securities		4		(0)
Deferred income taxes on unrealized holding (gain)loss		(2)		0
Balance, end of period	$	10	$	5

(8) Fair Value Measurements. The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets. The following table provides financial assets carried at fair value measured as of June 30, 2015:

			Fair Value Measurements Using
Description	Total Fair Value at 6/30/2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3 )
Equities	$	59	$	59	$	0	$	0

(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

General

UTMD manufactures and markets a well-established range of specialty medical devices. The Company’s Form 10-K Annual Report for the year ended December 31, 2014 provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. Because of the relatively short span of time, results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole. Currency amounts in the report are in thousands, except per-share amounts or where otherwise noted. Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; and EUR = Euros.

Analysis of Results of Operations

a) Overview

In the second calendar quarter (2Q) and first half (1H) of 2015, UTMD achieved results which are on track to meet its previously announced goals for 2015, despite greater than expected foreign currency exchange (FX) rate headwinds. The key issue in comparing 2015 financial results to 2014 results is FX. The FX headwinds reduced consolidated USD sales and had a leveraged negative effect on consolidated USD Gross Profit.

Income statement results in 2Q and 1H 2015 compared to the same periods of 2014 follow:

		2Q 2015		2Q 2014	change				1H 2015		1H 2014	change
Net Sales	$	10,397	$	10,491		(0.9	%)	$	20,630	$	20,318		+1.5	%
Gross Profit		6,099		6,349		(3.9	%)		12,211		12,399		(1.5	%)
Operating Income		3,967		4,062		(2.3	%)		7,844		7,905		(0.8	%)
Income Before Tax		3,924		3,930		(0.1	%)		7,592		7,712		(1.6	%)
Net Income		2,918		2,834		+3.0	%		5,586		5,556		+0.5	%
Earnings per Diluted Share		.773		.751		+3.0	%		1.480		1.470		+0.6	%

UTMD’s FX rates for income statement purposes are transaction-weighted averages. The average rates from the applicable foreign currency to USD during 2Q and 1H 2015 compared to the same periods of 2014 follow:

	2Q 2015	2Q 2014	change			1H2015	1H 2014	change
GBP	1.531	1.682		(9.0	%)	1.522	1.669		(8.8	%)
EUR	1.110	1.370		(18.9	%)	1.114	1.371		(18.7	%)
AUD	0.778	0.933		(16.5	%)	0.781	0.917		(14.8	%)

Total GAAP consolidated sales in 2Q 2015 were $94 lower than in 2Q 2014, but $312 higher in 1H 2015 than in 1H 2014. Using the same FX rates in 2015 as existed during the same periods in 2014 (“constant FX”), 2Q 2015 consolidated sales would have been $475 higher, and 1H 2015 sales would have been $872 higher. In other words, non-GAAP constant FX consolidated sales were up 4% in 2Q 2015 compared to 2Q 2014, and up 6% in 1H 2015 compared to 1H 2014. Approximately one-third of UTMD’s sales were invoiced in foreign currencies. The weighted average FX rate on foreign currency invoiced sales was about 13% lower in 2015 than in 2014.

UTMD profit margins in 2Q 2015 and 1H 2015 compared to 2Q 2014 and 1H 2014 follow:

	2Q 2015		2Q 2014		1H 2015		1H 2014
Gross Profit Margin (gross profit/ sales):	58.7	%	60.5	%	59.2	%	61.0	%
Operating Income Margin (operating profit/ sales):	38.2	%	38.7	%	38.0	%	38.9	%
EBT Margin (profit before income taxes/ sales):	37.7	%	37.5	%	36.8	%	38.0	%
Net Income Margin (profit after taxes/ sales):	28.1	%	27.0	%	27.1	%	27.3	%

UTMD’s 2Q and 1H 2015 Gross Profit Margins (GPMs) were lower than in 2Q and 1H 2014 due to the impact of a stronger USD on the cost of goods purchased in fixed USD terms by foreign subsidiaries, along with a less favorable product mix.

UTMD’s Operating Income Margins in 2015 were less diluted than its GPM since the lower FX rates reduced foreign subsidiary operating expenses in USD terms. Operating expenses were 20.5% of sales in 2Q 2015 compared to 21.8% of sales in 2Q 2014, and were 21.2% of sales in 1H 2015 compared to 22.1% of sales in 1H 2014.

Income Before Tax (EBT) of $3,924 (37.7% of sales) in 2Q 2015 was almost the same as $3,930 (37.5% of sales) in 2Q 2014 because of the lack of any interest expense in 2Q 2015 on loans required to finance the acquisition of Femcare in 2011, which had been fully repaid in 1Q 2015. Interest expense in 2Q 2014 was $78. On the other hand, 1H 2015 EBT of $7,592 (36.8% of sales) was $120 lower than 1H 2014 EBT of $7,712 (38.0% of sales), despite $100 lower interest expense, because of $61 lower operating income coupled with a $159 greater foreign currency exchange (FX) loss on the remeasured value of EUR cash balances in the UK. The value of EUR bank balances in USD terms declined by more than 8% during 1H 2015.

Net Income (NP) in 2Q 2015 of $2,918 (28.1% of sales) was 3% higher than the $2,834 (27.0% of sales) in 2Q 2014, with EBT about the same, as a result of a lower income tax provision. The average consolidated income tax provision rate was 25.6% in 2Q 2015 compared to 27.9% in 2Q 2014. NP in 1H 2015 was $5,586 (27.1% of sales) compared to $5,556 (27.4% of sales) in 1H 2014. The average consolidated income tax provision in 1H 2015 was 26.4% compared to 28.0% in 1H 2014. The lower average tax rates in 2015 were primarily due to 1) lower corporate income tax rates in the UK, and 2) a greater portion of UTMD’s consolidated EBT in Ireland, the sovereignty with the lowest tax rate.

Earnings per share (EPS) were $.773 in 2Q 2015 compared to $.751 in 2Q 2014, and $1.480 in 1H 2015 compared to $1.470 in 1H 2014. Diluted shares used to calculate EPS were 3,773,400 in 2Q 2015 compared to 3,774,700 in 2Q 2014. Diluted shares were 3,775,000 in 1H 2015 compared to 3,778,400 in 1H 2014. The 2015 decreases in diluted shares were due to less dilution from outstanding option shares and a small amount of shares repurchased in 2Q 2015.

UTMD’s FX rates for balance sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1H 2015 and the end of 1H 2014 follow:

	June 30, 2015		June 30, 2014		change
GBP		1.573		1.710		(8.1	%)
EUR		1.115		1.369		(18.5	%)
AUD		0.770		0.943		(18.3	%)

In addition to the FX impact on foreign subsidiary assets and liabilities, the changes in UTMD’s Balance Sheet at June 30, 2015 from December 31, 2014 resulted primarily from continued excellent cash generation, allowing paying off the remaining principal balances of loans obtained in 2011 to help finance the Femcare acquisition.

b) Revenues

The Company believes that revenue should be recognized at the time of shipment as title generally passes to the customer at the time of shipment, or completion of services performed under contract. Revenue recognized by UTMD is based upon documented arrangements and fixed contracts in which the selling price is fixed prior to acceptance and completion of an order. Revenue from product or service sales is generally recognized at the time the product is shipped or service completed and invoiced, and collectibility is reasonably assured. There are no post-shipment obligations which have been or are expected to be material to financial results.

There are circumstances under which revenue may be recognized when product is not shipped, which meet the criteria of SAB 104: the Company provides engineering services, for example, design and production of manufacturing tooling that may be used in subsequent UTMD manufacturing of custom components for other companies. This revenue is recognized when UTMD’s service has been completed according to a fixed contractual agreement.

Terms of sale are established in advance of UTMD’s acceptance of customer orders. In the U.S., Ireland, UK and Australia, UTMD generally accepts orders directly from and ships directly to end user clinical facilities, as well as third party med/surg distributors, under UTMD’s Standard Terms and Conditions (T&C) of Sale. About 14% of UTMD’s domestic end user sales go through third party med/surg distributors which contract separately with U.S. clinical facilities to provide purchasing, storage and scheduled delivery functions for the applicable facility. UTMD’s T&C of Sale are substantially the same in the U.S., Ireland, UK and Australia.

UTMD may have separate discounted pricing agreements with a clinical facility or group of affiliated facilities based on volume of purchases. Pricing agreements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes determine the fixed price by part number for the next agreement period of one or two years. For new customers, the customer’s best estimate of volume is accepted by UTMD for determining the ensuing fixed prices for the agreement period. New customers typically have one-year agreements. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD’s disclosure above that the selling price is fixed prior to the acceptance of a specific customer order.

Total GAAP consolidated sales in 2Q 2015 were $94 lower than in 2Q 2014, but $312 higher in 1H 2015 than in 1H 2014. In constant FX, 2Q 2015 consolidated sales would have been $475 higher, and 1H 2015 sales would have been $872 higher. In other words, non-GAAP constant FX consolidated sales were up 4% in 2Q 2015 compared to 2Q 2014, and up 6% in 1H 2015 compared to 1H 2014.

An easy way to think about the FX impact on consolidated UTMD sales follows: About one-third of UTMD sales are in currencies other than the USD (two-thirds of international sales). If the USD is 12% stronger for the applicable period(s) as a weighted average for all foreign currencies combined, then the impact is about a 4% decrease in consolidated USD sales (one-third of 12%). This is essentially what happened in 1H 2015. Since actual 1H 2015 consolidated USD sales were up 2%, constant FX USD sales for 1H 2015 were up 6%.

The most helpful categories of increased sales in 1H 2015 compared to 1H 2014, were 1) the resumption of purchases by UTMD’s China distributor of Deltran blood pressure monitoring (BPM) transducer kits, which were $775 in 1H 2015 compared to zero in 1H 2014, and 2) a $314 increase in neonatal device sales to third party international distributors. Both of these categories of international sales were invoiced in USD terms.

Despite the two improved international sales categories above, international sales as a whole in 2Q 2015 were $229 (4%) lower than in 2Q 2014, and in 1H 2015 were $359 (3%) lower than in 1H 2014. About two-thirds of total international sales were invoiced in weaker foreign currencies. Using constant FX rates, 2Q 2015 international sales would have been $246 higher (+5%) rather than $229 lower, and 1H 2015 international sales would have been $513 higher (+5%) rather than $359 lower.

Ireland subsidiary shipments, including trade sales to international third parties as well as intercompany sales, were EUR 1,542 in 2Q 2015 compared to EUR 670 in 2Q 2014, and EUR 3,269 in 1H 2015 compared to 1,142 in 1H 2014. The large increases resulted from trade sales of blood pressure monitoring (BPM) kits to UTMD’s China distributor in 2015 which did not occur in 2014, trade shipments of Filshie Sterishot kits, manufactured by UTMD Ireland in 1H 2015, directly to international customers located outside the UK, and intercompany shipments of Sterishot kits to UTMD subsidiaries in the UK and Australia for direct distribution to end user facilities within their local markets. Although 2Q 2015 Ireland direct domestic sales to end user facilities in Ireland were up 17% in EUR terms, they were down 5% in USD terms because of the weaker EUR. First half 2015 Ireland domestic sales were up 13% in EUR terms, but were down 8% in USD terms.

Sales by UTMD’s UK subsidiary, Femcare-Nikomed Ltd, were GBP 1,738 in 2Q 2015 compared to GBP 2,330 in 2Q 2014, and GBP 3,867 in 1H 2015 compared to GBP 4,711 in 1H 2014. As noted above, trade sales of Sterishot kits to international customers outside the UK which were included in UK sales in 1H 2014 were shipped directly from UTMD Ireland in 1H 2015. In addition, intercompany sales of Sterishot kits to Australia which were included in 1H 2014 UK sales were shipped directly from UTMD Ireland in 1H 2015. UK direct domestic sales to end user facilities in the UK in 2Q 2015 were 6% lower in GBP terms, but 15% lower in USD terms because of the weaker GBP. First half 2015 UK domestic sales were 10% lower in GBP terms, but were down 19% in USD terms.

UK subsidiary sales to Femcare’s U.S. distributor of the Filshie Clip System (which are included in the U.S. domestic sales category and are invoiced in USD) were up $60 (5% higher) in 2Q 2015, and up $330 (14% higher) in 1H 2015.

All sales by UTMD’s Australia subsidiary, Femcare Australia Pty Ltd, are domestic trade sales to end user facilities in Australia. In 2Q 2015, Australia sales were essentially the same in AUD terms as in 2Q 2014, but because of the weaker AUD, were 17% lower in USD. For 1H 2015, Australia subsidiary sales were AUD 1,636 ($1,278) compared to AUD 1,677 ($1,537) in 1H 2014.

As a result of the FX rate changes, consolidated USD international sales were only 49% of total consolidated sales in 2Q 2015 compared to 51% in 2Q 2014, and 48% of 1H 2015 sales compared to 51% of 1H 2014 sales. International sales exported from the U.S. in fixed USD terms were 8% higher in 2Q 2015, and 12% higher in 1H 2015, compared to the same periods of 2014, while international sales by UTMD’s foreign subsidiaries converted USD were 9% lower in 2Q 2015, and 8% lower in 1H 2015, compared to the same periods of 2014. Constant FX international sales by UTMD foreign subsidiaries in 2Q 2015 were up 4% rather than down 8%, and in 1H 2015 were up 3% rather than down 9%.

U.S. domestic sales, which include direct sales to U.S. clinical user facilities, sales of the Filshie Clip System to CooperSurgical, Inc. (CSI) and sales to U.S. OEM customers were $5,277 in 2Q 2015 (3% higher) compared to $5,142 in 2Q 2014, and $10,654 in 1H 2015 (7% higher) compared to $9,984 in 1H 2014. Direct sales of devices to U.S. user facilities were up $42 (1% higher) in 2Q 2015 and up $157 (2% higher) in 1H 2015. In addition to Filshie Clip System sales to CSI up $60 (5% higher) in 2Q 2015 and up $330 (14% higher) in 1H 2015, UTMD’s sales of components and finished devices to other U.S. companies for use in their products (OEM customers) were up $33 (6% higher) in 2Q 2015 and up $183 (18% higher) in 1H 2015.

The following table provides USD denominated sales divided into general product categories for total sales, and the subset of international sales:

Global revenues by product category:

		2Q 2015		2Q 2014		1H 2015		1H 2014
Obstetrics	$	1,174	$	1,134	$	2,309	$	2,303
Gynecology/ Electrosurgery/ Urology		5,758		6,282		11,712		12,403
Neonatal		1,680		1,538		3,213		2,810
Blood Pressure Monitoring and Accessories*		1,785		1,537		3,396		2,802
Total:	$	10,397	$	10,491	$	20,630	$	20,318

International revenues by product category:

		2Q 2015		2Q 2014		1H 2015		1H 2014
Obstetrics	$	197	$	156	$	382	$	324
Gynecology/ Electrosurgery/ Urology		3,325		3,952		6,736		7,848
Neonatal		565		403		1,020		705
Blood Pressure Monitoring and Accessories*		1,033		838		1,838		1,458
Total:	$	5,120	$	5,349	$	9,976	$	10,335

*includes molded components sold to OEM customers.

c) Gross Profit

Gross profits (GP) result from subtracting the cost of manufacturing products (direct materials, direct labor and manufacturing overhead), or the purchase price of finished products which are resold, from revenues. At UTMD, manufacturing overhead costs fully absorb indirect costs including depreciation on manufacturing equipment and facilities, quality assurance, materials requirements planning and purchasing, manufacturing engineering, production supervision, shipping, royalties paid to other entities and health plan benefits for both direct and indirect manufacturing personnel. UTMD’s GP margin (GPM) is GP as a percentage of revenues. In 2Q 2015, GP were $6,099 (58.7% GPM) compared to $6,349 (60.5% GPM) in 2Q 2014. In 1H 2015, GP were $12,211 (59.2% GPM) compared to $12,399 (61.0% GPM) in1H 2014. With a stronger USD, the consolidated GPM is squeezed, assuming that unit prices to customers invoiced in foreign currencies are kept constant, because raw materials and finished devices sold to UTMD’s foreign subsidiaries in fixed USD increase the cost of goods sold by the foreign subsidiary. In addition, 2Q and 1H 2015 product mix was less favorable than in 2Q and 1H 2014. BPM kit sales to UTMD’s China distributor, at a low GPM, were 3.8% of total consolidated sales in 1H 2015 compared to none in 1H 2014.

d) Operating Income (OP)

OP is the profit remaining after subtracting operating expenses from GP. Operating expenses include sales and marketing (S&M) expenses, product development (R&D) expenses and general and administrative (G&A) expenses. UTMD’s OP margin (OPM) is its operating income divided by revenues. OP in 2Q 2015 was $3,967 (38.2% OPM) compared to $4,062 (38.7% OPM) in 2Q 2014, and $7,844 (38.0% OPM) in 1H 2015 compared to $7,905 (38.9% OPM) in 1H 2014. Even though GP were $250 and $188 lower in 2Q 2015 and 1H 2015 respectively, compared to the prior year’s same periods, OP were just $95 and $61 lower in 2Q 2015 and 1H 2015, respectively.

Consolidated 2Q 2015 operating expenses were $2,132 compared to $2,287 in 2Q 2014. Operating expenses in 1H 2015 were $4,367 compared to $4,494 in 1H 2014. For consolidating foreign subsidiary expenses, the lower 2015 FX rates were helpful. In constant FX, 2Q 2015 and 1H 2015 operating expenses of UTMD foreign subsidiaries in the aggregate would have been $127 and $242 higher, respectively.

Consolidated S&M expenses in 2Q 2015 were $552 (5.3% of sales) compared to $608 (5.8% of sales) in 2Q 2014. Consolidated S&M expenses in 1H 2015 were $1,125 (5.5% of sales) compared to $1,150 (5.7% of sales) in 1H 2014. S&M expenses in 2Q of both 2015 and 2014 included $70 in U.S. Medical Device Excise Tax (MDET). The MDET was $138 in 1H 2015 compared to $136 in 1H 2014. The MDET, imposed as a component of the Patient Protection and Affordable Care Act (Obamacare), is levied as a 2.3% excise tax on domestic sales of medical devices.

S&M expenses include all customer support costs including training. In general, training is not required for UTMD’s devices since they are well-established and have been clinically widely used. Written “Instructions For Use” are packaged with all finished devices. Although UTMD does not have any explicit contracts with customers to provide training, it does have agreements in the U.S. and UK under which it agrees to provide hospital members inservice and clinical training as required and reasonably requested.

UTMD promises prospective customers that it will provide, at no charge in reasonable quantities, copies of instruction materials developed for the use of its devices. UTMD provides customer support from offices in the U.S., UK, Ireland and Australia by telephone, and employed representatives on a geographically dispersed basis, to answer user questions and help troubleshoot any user issues. Occasionally, on a case-by-case basis, UTMD may utilize the services of an independent practitioner to provide educational assistance to clinicians. All inservice and training expenses are routinely expensed as they occur. All of these services are allocated from S&M overhead costs included in Operating Expenses. Historically, marginal consulting costs have been immaterial to financial results.

R&D expenses were $140 (1.4% of sales) in 2Q 2015 compared to $115 (1.1% of sales) in 2Q 2014, and $296 (1.4% of sales) in 1H 2015 compared to $238 (1.2% of sales) in 1H 2014.

Consolidated G&A expenses in 2Q 2015 were $1,439 (13.8% of sales) compared to $1,564 (14.9% of sales) in 2Q 2014, and $2,946 (14.3% of sales) in 1H 2015 compared to $3,106 (15.3% of sales) in 1H 2014. The G&A expenses in 2Q 2015 included $618 (5.9% of sales) of non-cash expense from the amortization of identifiable intangible assets (IIA) resulting from the Femcare acquisition in 2011, which were $679 (6.5% of sales) in 2Q 2014. The $61 difference was due to FX rate conversion into USD since the IIA amortization expense in GBP was the same in both periods. IIA amortization expense for 1H 2015 and 1H 2014 were $1,230 (6.0% of sales) and $1,347 (6.6% of sales), respectively, with the $117 lower 2015 expense again being due to FX rate differences.

G&A expenses also include the cost of outside financial auditors and corporate governance activities related to the implementation of SEC rules resulting from the Sarbanes-Oxley and Dodd-Frank Acts, as well as estimated stock-based compensation cost, a noncash expense. Option compensation expense included in G&A expenses was $22 in 2Q 2015 compared to $18 in 2Q 2014, and $44 in 1H 2015 compared to $24 in 1H 2014.

Operating expense summary:

		2Q 2015		2Q 2014		1H 2015		1H 2014
S&M Expense	$	552	$	608	$	1,125	$	1,150
R&D Expense		140		115		296		238
G&A Expense		1,439		1,564		2,946		3,106
Total Operating Expenses:	$	2,132	$	2,287	$	4,367	$	4,494

e) Non-operating expense (NOE)/ Non-operating income (NOI)

Net NOE includes 1) loan interest, 2) bank fees and 3) FX loss from remeasuring the USD value of EUR cash bank balances in the UK and GBP cash balances in Ireland, minus non-operating income from 1) rent of underutilized property, 2) investment income and 3) royalties received from licensing the Company’s technology. Net NOE in 2Q 2015 was $43 compared to $132 in 2Q 2014, and $252 in 1H 2015 compared to $193 in 1H 2014. The 2Q 2015 lower Net NOE resulted from the lack of any interest on debt, which was $78 in 2Q 2014. For 1H 2015, the increase in Net NOE was due to recognizing $159 higher currency translation loss on remeasured foreign currency cash balances, less $100 lower interest expense on loans fully repaid in 1Q 2015.

f) Income Before Tax (EBT)

EBT results from subtracting NOE from OP. 2Q 2015 consolidated EBT was $3,924 (37.7% of sales) compared to $3,930 (37.5% EBTM) in 2Q 2014. 2Q EBT was about the same in both 2015 and 2014 because $89 lower NOE almost offset the $95 lower OP. 1H 2015 consolidated EBT was $7,592 (36.8% of sales) compared to $7,712 (38.0% of sales) in 1H 2014. The $120 lower 1H 2015 EBT resulted from $61 lower operating income coupled with a $159 greater foreign currency exchange (FX) loss on the remeasured value of EUR cash balances in the UK, less $100 lower interest expense.

The EBT of UTMD Ltd. (Ireland) was EUR 1,272 in 1H 2015 compared to EUR 223 in 1H 2014. The EBT of Femcare Group Ltd (Femcare-Nikomed, Ltd., UK and Femcare Australia) was GBP 1,709 in 1H 2015 compared to GBP 2,239 in 1H 2014. The differences are due primarily to the fact that in 2014, Filshie Sterishot kits were purchased from third party vendors and shipped from Femcare-Nikomed in the UK to international customers, while in 2015 the kits are being manufactured by UTMD in-house in Ireland and shipped and invoiced to international customers directly from UTMD Ltd in Ireland.

Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2015 consolidated EBT excluding the remeasured bank balance currency loss and interest expense (“Non-GAAP adjusted consolidated EBITDA”) were $4,793 compared to $4,946 in 2Q 2014. The $153 lower non-GAAP adjusted consolidated EBITDA resulted primarily from $78 lower interest expense, plus $250 lower GP offset by $155 lower operating expenses and $61 lower IIA amortization expense emanating from the significant FX rate changes. Non-GAAP adjusted consolidated EBITDA in 1H 2015 were $9,491 compared to $9,659 in 1H 2014. The $168 lower non-GAAP EBITDA resulted from $100 lower interest expense plus the combination of the following differences emanating primarily from FX rate changes: 1) $188 lower GP offset by $127 lower operating expenses, 2) $117 lower USD-denominated IIA amortization expense, and 3) $158 higher loss from remeasured foreign currency bank balances.

g) Net Income (NP)

NP is EBT minus a provision for income taxes. Despite the negative impact of FX rates on sales, GP and the remeasured value of foreign currency bank balances, UTMD achieved higher NP in 2Q 2015 ($2,918) than in 2Q 2014 ($2,834). Similarly, NP in 1H 2015 ($5,586) was slightly higher than the NP in 1H 2014 ($5,556). In addition to factors described in EBT, this was due to a lower average income tax provision rate. The average consolidated income tax provisions (as a % of EBT) in 2Q 2015 and 1H 2015 were 25.6% and 26.4%, respectively, compared to 27.9% and 28.0% in 2Q 2014 and 1H 2014 respectively.

The combined income tax provision rate was lower in 2Q and 1H 2015 compared to 2Q and 1H 2014 because of a reduced corporate income tax rate in the UK, and because UTMD Ltd (Ireland), taxed at the lowest rate of all sovereignties, had a larger share of total EBT in 2Q and 1H 2015 compared to those periods of 2014.

UTMD’s combined state and federal income tax provision rate in the U.S. after all allowable deductions was 33.4% in 2Q 2015 compared to 34.5% in 2Q 2014, and 33.8% in 1H 2015 compared to 34.2% in 1H 2014. The corporate income tax rate in the UK was 20% in 2Q 2015 compared to 21% in 2Q 2014, and 21% in 1Q 2015 compared to 23% in 1Q 2014. The income tax rate in Australia remained 30% in both years’ periods. The UTMD Ltd (Ireland) tax rate on export profits remains 12.5%. A number of factors, such as the mix of EBT from subsidiaries with differing income tax rates and the amount of U.S. deductions such as the R&D tax credit, result in period to period tax provision fluctuations. UTMD’s income tax provision is trued-up each quarter for cumulative year-to-date estimated income tax liability.

NP divided by revenues is UTMD’s Net Income margin (NPM). The NPM was 28.1% and 27.1% in 2Q 2015 and 1H 2015 respectively. The NPM for 2Q 2014 and 1H 2014 was 27.0% and 27.4% respectively.

h) Earnings Per Share (EPS)

EPS are consolidated NP divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are “in the money,” i.e. have exercise prices below the applicable period’s weighted average stock market value). Diluted EPS were $0.773 in 2Q 2015 compared to $0.751 in 2Q 2014, and $1.480 in 1H 2015 compared to $1.470 in 1H 2014. EPS were up as a result of higher NP divided by slightly fewer diluted shares. EPS benefited from the open market purchase of 4,000 shares during 2Q 2015. EPS for the most recent twelve months were $3.02.

The weighted average number of diluted shares outstanding used to calculate 2Q 2015 EPS declined to 3,773,431 from 3,774,680 in 2Q 2014. The number of shares added as a dilution factor in 2Q 2015 was 18,521 compared to 24,557 in 2Q 2014. Increases and decreases in UTMD’s stock price impact EPS as a result of the dilution calculation for unexercised options with exercise prices below the average stock market value during each period.

Diluted shares outstanding used to calculate 1H 2015 EPS declined to 3,774,964 from 3,778,395 in 1H 2014. The number of shares added as a dilution factor in 1H 2015 was 22,359 compared to 28,487 in 1H 2014.

Actual outstanding shares at the end of 2Q 2015 were 3,757,200 which included 2Q 2015 employee and outside director option exercises of 13,632 shares. The number of shares used for calculating earnings per share was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. The total number of outstanding unexercised employee and outside director options at June 30, 2015 was 67,719 shares at an average exercise price of $38.75/ share, including shares awarded but not vested. This compares to 108,080 unexercised option shares outstanding at June 30, 2014 at an average exercise price of $35.68/ share. No option shares have been awarded to date in 2015.

UTMD repurchased 4,000 of its shares in the open market during 2Q 2015 at an average cost, including commissions and fees, of $53.87 per share ($215 total). Since no shares were repurchased in 1Q 2015, this is also the amount for 1H 2015. The Company repurchased 17,344 shares in 2Q 2014 at an average cost of $47.18 per share ($818 total). Since no shares were repurchased in 1Q 2014, this is also the amount for 1H 2014. UTMD retains its program for repurchasing shares when they seem undervalued.

i) Return on Equity (ROE)

ROE is the NP retained by UTMD to internally finance its growth, divided by the average accumulated shareholders’ equity for the applicable time period. Annualized ROE in 1H 2015 (before payment of dividends to shareholders) was 17% compared to 18% in 1H 2014. The lower ROE in 1H 2015, in spite of higher NP, was due to 6% growth in average 1H 2015 shareholders’ equity compared to 1H 2014. Targeting a high ROE over 20% remains a key financial objective for UTMD management. ROE can be increased by effectively deploying capital to increase NP, or by reducing shareholders’ equity by paying cash dividends to shareholders or particularly by repurchasing shares.

Liquidity and Capital Resources

j) Cash flows

Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $5,733 in 1H 2015 compared to $5,760 in 1H 2014. The most significant change in the two periods was a $729 use of cash for lower accrued expenses, partially offset by a $690 benefit to cash from lower inventories. There was also a $188 benefit to cash from a lower increase in accounts receivable in 1H 2015 compared to 1H 2014.

The Company’s reduction of its bank loan principal balances was the most significant use of cash in both periods. UTMD repaid the remaining $4,778 principal balance as of December 31, 2014 in 1Q 2015, compared to $2,035 principal repaid during 1H 2014. UTMD made cash dividend payments to shareholders of $957 in 1H 2015 compared to $938 in 1H 2014, a 2% increase in dividends.

Capital expenditures for property and equipment (PP&E) were $109 in 1H 2015 compared to $836 in 1H 2014. UTMD paid $550 in 1H 2014 in completing its new distribution facility in Castle Hill NSW Australia. Depreciation of PP&E was $301 in 1H 2015 compared to $311 in 1H 2014. Except for the possibility of a facility purchase in the UK or an acquisition, planned capital expenditures during 2015 are expected to remain less than depreciation of PP&E. The Company continues to keep its facilities, equipment and tooling in good working order.

During 1H 2015, UTMD received a net of $203 and issued 12,825 shares of its stock upon the exercise of employee and director stock options. The shares issued were net of 5,794 shares retired upon optionees trading those shares in payment of the stock option exercise price and related taxes. Option exercises in 1H 2015 were at an average price of $28.36 per share. In comparison, in 1H 2014, the Company received $271 from issuing 16,412 shares of stock on the exercise of employee and director stock options, net of 5,049 shares retired upon optionees trading shares in payment of the stock option exercise price.

UTMD repurchased and retired 4,000 of its own shares during 1H 2015 at a cost of $215, compared to 17,344 shares repurchased in 1H 2014 at a cost of $818.

Management believes that income from operations and effective management of working capital will provide the liquidity needed to finance its internal growth plans. In addition, the Company may use cash for marketing or product manufacturing rights to broaden the Company's product offerings; for continued share repurchases when the price of the stock is undervalued; for cash dividends to stockholders; and if available for a reasonable price, an acquisition that might strategically fit UTMD’s business and be accretive to financial performance.

k) Assets and Liabilities

June 30, 2015 total consolidated USD assets were $1,146 lower than at December 31, 2014. The decrease was due to a $958 decrease in intangible assets from $1,259 1H 2015 period amortization offset by a stronger GBP converting the remaining UK balance into USD. UK subsidiary GBP-denominated assets were translated into USD at an FX rate 0.9% higher (stronger GBP) than the rate at the end of 2014. Other changes were a $910 increase in accounts and other receivables, $490 lower net PP&E book value from $192 in depreciation less new purchases, and a weaker EUR and AUD in UTMD Ltd (Ireland) and Femcare (Australia) where UTMD owns its facilities. UTMD’s Ireland subsidiary EUR-denominated assets were translated into USD at an FX rate 7.9% lower (weaker EUR) than the rate at the end of 2014. UTMD’s Australia subsidiary AUD-denominated assets were translated into USD at an FX rate 5.9% lower (weaker AUD) than the rate at the end of 2014. The $910 increase in accounts and other receivables remain well within management’s aging targets. Consolidated inventories declined $399, getting back to management’s targets after hedging for the start-up of manufacturing Sterishot II in Ireland. The principal balance of the JPMorgan Chase loans associated with the Femcare acquisition is now zero.

Working capital (current assets minus current liabilities) increased 19% to $24,643 at June 30, 2015, compared to $20,704 at December 31, 2014. Current liabilities decreased $3,638 due to elimination of the $3,894 current portion of notes payable as of December 31, 2014. Accrued liabilities increased $253 due to the 2Q 2015 quarterly dividend payment to shareholders accrued but not paid until after June 30, whereas the 4Q 2014 dividend was paid before the end of December 2014. UTMD management believes that its working capital remains sufficient to meet normal operating needs and projected cash dividend payments to shareholders.

At June 30, 2015 and December 31, 2014, net intangible assets including goodwill were 53% of total assets.

UTMD eliminated all of its remaining bank debt in February, 2015. The principal balance of bank debt at December 31, 2014 was 1) $1,750 to JP Morgan Chase in the U.S., of which $350 was long term debt, and 2) $3,117 (2,000 GBP) to JP Morgan Chase in the U.K., of which $2,494 (1,600 GBP) was long term debt. The deferred tax liability balance for Femcare identifiable intangible assets ($9,084 on the date of the acquisition), was $5,370 at June 30, 2015 compared to $5,581 at December 31, 2014. Reduction of the deferred tax liability occurs as the book/tax difference of amortization is eliminated over the remaining useful life of the Femcare identifiable intangible assets. UTMD’s total debt ratio (total liabilities/ total assets) as of June 30, 2015 declined to 15% compared to 20% as of December 31, 2014.

l) Management's Outlook.

As outlined in its December 31, 2014 SEC 10-K report, UTMD’s plan for 2015 is to

1) continue to exploit distribution and manufacturing synergies by further integrating capabilities and resources in its multinational operations;

2) introduce additional products helpful to clinicians through internal new product development;

3) continue achieving excellent overall financial operating performance;

4) utilize positive cash generation to eliminate debt remaining from the Femcare acquisition, continue cash dividends to shareholders and continue open market share repurchases if/when the UTMD share price seems undervalued; and

5) be vigilant for accretive acquisition opportunities which may be increasingly brought about by difficult burdens on small, innovative companies, including especially the MDET.

Despite the much larger than anticipated negative impact of FX rates on 1H 2015 sales and gross profits, operating performance in the first half of the 2015 year was on track to meet UTMD’s previously stated financial objectives for the year. However, continued strengthening of the USD relative to the GBP, EUR and AUD in 2H 2015 would likely put that in jeopardy for the year as a whole.

UTMD is now well-positioned financially for completing an acquisition that could significantly contribute to its future performance without diluting shareholder interest. Although some interesting opportunities were pursued in 1H 2015, it has become even more clear that UTMD needs to remain very patient and focused in order to meet its shareholder return criteria after operational consolidation with another entity, particularly if the target comes in an auction situation. Despite the very real and increasing burdens that make selling attractive to some business owners, valuations remain very high.

m) Accounting Policy Changes.

None.

Forward-Looking Information. This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. When used in this document, the words “anticipate,” “believe,” “project,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP) and in Australia denominated in the Australia Dollar (AUD). The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. The exchange rates were .8966, .8258 and .7305 EUR per USD as of June 30, 2015, December 31, 2014 and June 30, 2014, respectively. Exchange rates were .6359, .6416 and .5847 GBP per USD as of June 30, 2015, December 31, 2014 and June 30, 2014, respectively. Exchange rates were 1.2986, 1.2223 and 1.0609 AUD per USD on June 30, 2015, December 31, 2014 and June 30, 2014, respectively. UTMD manages its foreign currency risk without separate hedging transactions by conducting as much business in local currencies as is practicable, and by optimizing global account structures through liquidity management accounts.

Item 4. Controls and Procedures

The Company’s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of June 30, 2015. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of June 30, 2015, the Company’s disclosure controls and procedures were effective.

There were no changes in the Company’s internal controls over financial reporting that occurred during the quarter ended June 30, 2015, that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company may be a party from time to time in litigation incidental to its business. Presently, there is no litigation.

Item 1A. Risk Factors

In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in UTMD’s Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect its business, financial condition or future results. The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

Legislative healthcare reform in the United States, as embodied in The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (the “Acts”) adds a substantial excise tax that began in 2013, increases administrative costs and has lead to decreased revenues in the U.S.:

The voluminous Acts, administrative rules to enforce the Acts and promised efforts to reform the Acts, make the U.S. medical device marketplace unpredictable, particularly for the thousands of small medical device manufacturers including UTMD that do not have the overhead structure that the larger medical device companies can afford. To the extent that the Acts continue to place additional burdens on small medical device companies in the form of the excise tax on medical device sales, additional oversight of marketing and sales activities and new reporting requirements, the result is likely to continue to be negative for UTMD’s ability to effectively compete and support continued investments in new product development and marketing of specialty devices in the U.S.

Increasing regulatory burdens including premarketing approval delays may result in significant loss of revenue, unpredictable costs and loss of management focus on helping the Company thrive:

The Company’s experience in 2001-2005, when the FDA improperly sought to shut it down highlights the ongoing risk of being subject to a regulatory environment which can be arbitrary and capricious. The risks associated with such a circumstance relate not only to the substantial costs of litigation in millions of dollars, but also loss of business, the diversion of attention of key employees for an extended period of time, from new product development and routine quality control management activities, and a tremendous psychological and emotional toll on employees.

Since the FDA reserves to itself the interpretation of which vague industry standards comprise law at any point in time, it is impossible for any medical device manufacturer to ever be confident that it is operating within the Agency’s version of the law. The result is that companies, including UTMD, are considered guilty prior to proving their innocence.

New premarketing submission administrative burdens and substantial increases in “user fees” increase product development costs and result in delays to revenues from new or improved devices.

The growth of Group Purchasing Organizations (GPOs) adds non-productive costs, typically weakens the Company’s marketing and sales efforts and may result in lower revenues:

GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting their revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD’s, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. In any other industry, their business model based on “kickbacks” would be a violation of law. These bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily related to collection of their administrative fees.

The Company’s business strategy may not be successful in the future:

As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable regulatory environment, the Company’s views of the future and product/ market strategy may not yield financial results consistent with the past.

As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage:

An aging population and an extended economic recession are placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years. Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs. As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services. Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD’s clinical advantages much more difficult.

A product liability lawsuit could result in significant legal expenses and a large award against the Company:

UTMD’s devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case. In any lawsuit where an individual plaintiff suffers permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists.

The Company’s reliance on third party distributors in some markets may result in less predictable revenues:

UTMD’s distributors have varying expertise in marketing and selling specialty medical devices. They also sell other devices that may result in less focus on the Company’s products. In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, by copying, a distributor of UTMD’s products may eventually become a competitor with a cheaper but lower quality version of UTMD’s devices.

The loss of one or more key employees could negatively affect UTMD performance:

In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance. The Company’s benefits programs are key to recruiting and retaining talented employees. The rapid increase in UTMD’s employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.

Fluctuations in foreign currencies relative to the U.S. Dollar (USD) can result in significant differences in period to period financial results:

Since a significant portion of UTMD’s sales are outside the U.S. and consolidated financial results are reported in USD terms, a stronger USD can have negative effects. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand. For the portion invoiced in a foreign currency, not only USD denominated sales and profits are reduced, but also gross profits and operating profits in foreign currency terms are reduced because finished distributed products and/or U.S. made raw materials and components are being purchased in fixed USD.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table details purchases by UTMD of its own securities during 2Q 2015.

ISSUER PURCHASES OF EQUITY SECURITIES

Period	Total Number of Shares Purchased (1)		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)		Maximum Number (or Approximate Dollar Value) of Shares that May be Purchased Under the Plans or Programs (1)
4/01/15 – 4/30/15		2,000	$	54.05		2,000
5/01/15 – 5/31/15		2,000	$	53.68		2,000
6/01/15 – 6/30/15		-		-		-
Total		4,000	$	53.87		4,000

(1)

In 2Q 2015 UTMD repurchased the above shares pursuant to a continued open market repurchase program initially announced in August 1992. Since 1993 through 2Q 2015, the Company has repurchased 6.8 million shares at an average cost of $12.67 per share including broker commissions and fees in open market transactions. In addition, the Company conducted tender offer transactions in which it purchased an additional 2.8 million shares at an average cost of $9.76 per share including fees and administrative costs. In total, UTMD has repurchased 9.5 million of its shares at an average price of $11.82 per share since 1993. To complete the picture relating to current shares outstanding, since 1993 the Company’s employees and directors have exercised and purchased 1.9 million option shares at an average price of $10.97 per share. All options were awarded at the market value of the stock on the date of the award.

The frequency of UTMD’s open market share repurchases depends on the availability of sellers and the price of the stock. The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD’s continuing and long term consistent pattern of open market share repurchases.

The purpose of UTMD’s ongoing share repurchases is to maximize the value of the Company per share for its continuing shareholders, and maximize its return on shareholder equity by employing excess cash generated by effectively managing its business. Although UTMD has repurchased approximately 70% of its shares that were outstanding 22 years ago, it does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.

Item 6. Exhibits

Exhibit #	SEC Reference #	Title of Document

1	31	Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

2	31	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

3	32	Certification of CEO pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

4	32	Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

5	101 ins	XBRL Instance

6	101.xsd	XBRL Schema

7	101.cal	XBRL Calculation

8	101.def	XBRL Definition

9	101.lab	XBRL Label

10	101.pre	XBRL Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	UTAH MEDICAL PRODUCTS, INC.
	REGISTRANT

Date: 8/7/15	By: /s/ Kevin L. Cornwell
	Kevin L. Cornwell
	CEO

Date: 8/7/15	By: /s/ Paul O. Richins
	Paul O. Richins
	Principal Financial Officer

EX-31.1 2 utahmedicalexh311.htm CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 utahmedicalexh311.htm

Exhibit 31.1

Exhibit 1

CERTIFICATION OF CEO

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin L. Cornwell, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2015


/s/ Kevin L. Cornwell
Kevin L. Cornwell
Chief Executive Officer

EX-31.2 3 utahmedicalexh312.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 utahmedicalexh312.htm

Exhibit 31.2

Exhibit 2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul O. Richins, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2015


/s/ Paul O. Richins
Paul O. Richins
Principal Financial Officer

EX-32.1 4 utahmedicalexh321.htm CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. ?1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 utahmedicalexh321.htm

Exhibit 32.1

Exhibit 3

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

August 7, 2015

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 utahmedicalexh322.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. ?1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 utahmedicalexh322.htm

Exhibit 32.2

Exhibit 4

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul O. Richins, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Paul O. Richins

Paul O. Richins

Principal Financial Officer

August 7, 2015

EX-101.INS 6 utmd-20150630.xml XBRL INSTANCE

59000

58000

5613000

4703000

662000

768000

29976000

29675000

7746000

8236000

15216000

15145000

40015000

39675000

13023000

11655000

26992000

28020000

79930000

81076000

932000

929000

4401000

4148000

3894000

5333000

8971000

973000

5370000

5581000

1034000

995000

11737000

16520000

38000

37000

-3408000

-3234000

3029000

2890000

68534000

64863000

68193000

64556000

79930000

81076000

0.01

5000000

0.01

50000000

3757000

3748000

3757000

3748000

10397000

10491000

20630000

20318000

4298000

4142000

8419000

7919000

6099000

6349000

12211000

12399000

1992000

2172000

4071000

4256000

140000

115000

296000

238000

2132000

2287000

4367000

4494000

3967000

4062000

7844000

7905000

-43000

-132000

-252000

-193000

3924000

3930000

7592000

7712000

1006000

1096000

2006000

2156000

2918000

2834000

0.78

0.76

1.49

1.48

0.77

0.75

1.48

1.47

3755000

3750000

3753000

3750000

3773000

3775000

3778000

2360000

859000

-175000

1110000

2000

1000

-3000

5280000

3693000

5412000

6663000

2000

-2000

5586000

5556000

301000

311000

1259000

1376000

-9000

6000

-1000

-4000

-213000

-282000

44000

24000

828000

1016000

81000

31000

-218000

472000

-104000

-118000

5000

91000

-654000

75000

147000

204000

5733000

5760000

109000

836000

7000

-116000

-836000

245000

271000

-215000

-818000

42000 0

107000

120000

4778000

2035000

957000

938000

-5640000

-3400000

-82000

20000

-105000

1544000

19274000

14395000

19169000

15939000

2781000

1551000

65000

167000

10-Q 2015-06-30 false UTAH MEDICAL PRODUCTS INC 0000706698 utmd --12-31 3758300 199695980 Accelerated Filer Yes No No 2015 Q2

(1)  The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States.  These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2014.  In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations.  Currency amounts are in thousands except per-share amounts and where noted.

(2)           Recent Accounting Standards. In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted.  UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

(3) Inventories at June 30, 2015 and December 31, 2014 consisted of the following:   <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> June 30, 2015 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> December 31, 2014 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Finished goods </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="144" valign="top" style='width:1.5in;border:none;background:#CCEEFF;padding:0'> 1,554 </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="135" valign="top" style='width:101.0pt;border:none;background:#CCEEFF;padding:0'> 1,847 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> Work-in-process </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;padding:0'> 1,101 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;padding:0'> 1,103 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Raw materials </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> 1,818 </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> 1,922 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> Total </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> $ </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:double windowtext 1.5pt;padding:0'> 4,473 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> $ </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> 4,872 </td> </tr> </table>

(4) Stock-Based Compensation. At June 30, 2015, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.  The Company accounts for stock compensation under FASB Accounting Standards Codification (ASC) 718, Stock Compensation.  This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.  In the quarters ended June 30, 2015 and 2014, the Company recognized  $22 and $18, respectively, in stock-based compensation cost. In the six months ended June 30, 2015 and 2014, the Company recognized $44 and $24, respectively, in stock based compensation cost.

(5)  Notes Payable.  In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. and a $12,934 loan from JP Morgan Chase, London Branch to help finance UTMDs purchase of Femcare.  The notes were fully paid off in February 2015.

(6)   Warranty Reserve.   The Companys published warranty is: UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment.  During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.   UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2014 or June 30, 2015.

(7)   Investments.  Changes in the unrealized holding gain/loss on investment securities available-for-sale and reported as a separate component of accumulated other comprehensive income are as follows:   <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="top" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2Q 2015 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="top" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2Q 2014 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Balance, beginning of period </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;background:#CCEEFF;padding:0'> 8 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;background:#CCEEFF;padding:0'> 5 </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;padding:0'> Realized loss from securities included in beginning balance </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;padding:0'> ~ </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;padding:0'> ~ </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;background:#CCEEFF;padding:0'> Gross unrealized holding gains (losses), in equity securities </td> <td width="9" valign="top" style='width:6.5pt;background:#CCEEFF;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;background:#CCEEFF;padding:0'> 4 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;background:#CCEEFF;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;background:#CCEEFF;padding:0'> (0) </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;padding:0'> Deferred income taxes on unrealized holding (gain) loss </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> (2) </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 0 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Balance, end of period </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 10 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'>  5 </td> </tr> </table>

(8)  Fair Value Measurements.  The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets.  The following table provides financial assets carried at fair value measured as of June 30, 2015:   <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="96" valign="top" style='width:1.0in;padding:0'>   </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="96" valign="top" style='width:1.0in;padding:0'>   </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td colspan="8" valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Fair Value Measurements Using </td> </tr> <tr align="left"> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Description </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Total Fair Value at 6/30/2015 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>  Quoted Prices in Active Markets for Identical Assets (Level 1) </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>  Significant Other Observable Inputs (Level 2) </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> Significant Unobservable Inputs (Level 3 ) </td> </tr> <tr align="left"> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> Equities </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> 59 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 59 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 0 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 0 </td> </tr> </table>

(9) Subsequent Events.  UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted.  UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

<table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> June 30, 2015 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> December 31, 2014 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Finished goods </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="144" valign="top" style='width:1.5in;border:none;background:#CCEEFF;padding:0'> 1,554 </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="135" valign="top" style='width:101.0pt;border:none;background:#CCEEFF;padding:0'> 1,847 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> Work-in-process </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;padding:0'> 1,101 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;padding:0'> 1,103 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Raw materials </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> 1,818 </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> 1,922 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> Total </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> $ </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:double windowtext 1.5pt;padding:0'> 4,473 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> $ </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> 4,872 </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="top" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2Q 2015 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="top" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 2Q 2014 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Balance, beginning of period </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;background:#CCEEFF;padding:0'> 8 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;background:#CCEEFF;padding:0'> 5 </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;padding:0'> Realized loss from securities included in beginning balance </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;padding:0'> ~ </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;padding:0'> ~ </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;background:#CCEEFF;padding:0'> Gross unrealized holding gains (losses), in equity securities </td> <td width="9" valign="top" style='width:6.5pt;background:#CCEEFF;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;background:#CCEEFF;padding:0'> 4 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;background:#CCEEFF;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;background:#CCEEFF;padding:0'> (0) </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;padding:0'> Deferred income taxes on unrealized holding (gain) loss </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> (2) </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 0 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Balance, end of period </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 10 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'>  5 </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="96" valign="top" style='width:1.0in;padding:0'>   </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="96" valign="top" style='width:1.0in;padding:0'>   </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td colspan="8" valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Fair Value Measurements Using </td> </tr> <tr align="left"> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Description </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Total Fair Value at 6/30/2015 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>  Quoted Prices in Active Markets for Identical Assets (Level 1) </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>  Significant Other Observable Inputs (Level 2) </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> Significant Unobservable Inputs (Level 3 ) </td> </tr> <tr align="left"> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> Equities </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> 59 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 59 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 0 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 0 </td> </tr> </table>

1554000

1847000

1101000

1103000

1818000

1922000

4473000

4872000

22000

18000

44000

24000

14000000

12934000

8000 5000

4000

-2000

10000 5000

59000

0000706698 2015-01-01 2015-03-31 0000706698 2014-12-31 0000706698 2014-01-01 2014-03-31 0000706698 2013-12-31 0000706698 2014-06-30 0000706698 2015-01-01 2015-06-30 0000706698 2015-06-30 0000706698 2015-04-01 2015-06-30 0000706698 2014-04-01 2014-06-30 0000706698 2014-01-01 2014-06-30 0000706698 fil:JPMorganChaseBankNAChaseNoteMember 2015-06-30 0000706698 fil:JPMorganChaseLondonBranchNoteMember 2015-06-30 0000706698 us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000706698 us-gaap:FairValueInputsLevel1Member 2015-06-30 0000706698 us-gaap:FairValueInputsLevel2Member 2015-06-30 0000706698 us-gaap:FairValueInputsLevel3Member 2015-06-30 0000706698 2015-03-31 0000706698 2014-03-31 0000706698 2015-08-06 iso4217:USD shares iso4217:USD shares

EX-101.SCH 7 utmd-20150630.xsd XBRL SCHEMA 000160 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Investments: Available-for-sale Securities (Details) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Warranty Reserve link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Inventories: Schedule of Inventory, Current (Details) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Investments: Available-for-sale Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Investments link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 utmd-20150630_cal.xml XBRL CALCULATION EX-101.DEF 9 utmd-20150630_def.xml XBRL DEFINITION EX-101.LAB 10 utmd-20150630_lab.xml XBRL LABEL Available-for-sale Securities {1} Available-for-sale Securities New Accounting Pronouncements, Policy Warranty Reserve Common stock purchased and retired Prepaid expenses and other current assets Prepaid expenses and other current assets CASH FLOWS FROM OPERATING ACTIVITIES: Provision for income taxes Operating income Operating income Total current assets Total current assets Inventories Total ASSETS Entity Registrant Name Fair Value, Inputs, Level 2 Fair Value, Hierarchy [Axis] Fair Value, Measurements, Recurring Measurement Frequency [Axis] Statement [Line Items] Cash paid during the period for interest Net increase (decrease) in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Payment of taxes for exchange of stock options Payment of taxes for exchange of stock options Represents the monetary amount of Payment of taxes for exchange of stock options, during the indicated time period. Net cash provided by operating activities Net cash provided by operating activities Other income (expense) Income Statement Deferred income taxes Accounts payable Current assets: Entity Filer Category Current Fiscal Year End Date Document Type Available-for-sale Securities, Gross Unrealized Gain (Loss) Raw materials Notes Payable {1} Notes Payable (Gain) loss on disposal of assets (Gain) loss on disposal of assets Stockholders' equity: Entity Well-known Seasoned Issuer Fair Value, Measurement Frequency JP Morgan Chase London Branch Note Basis of Presentation Net cash provided by (used in) financing activities Net cash provided by (used in) financing activities Total current liabilities Total current liabilities TOTAL ASSETS TOTAL ASSETS Document Fiscal Period Focus CASH FLOWS FROM INVESTING ACTIVITIES: Accounts receivable Accounts receivable Earnings per common share (diluted) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2015, 3,757 shares and December 31, 2014, 3,748 shares Cash {1} Cash Cash at beginning of period Cash at end of period Document and Entity Information: Debt Instrument, Face Amount Inventories {2} Inventories Amortization Income before provision for income taxes Income before provision for income taxes LIABILITIES AND STOCKHOLDERS' EQUITY Entity Central Index Key Tables/Schedules Stock-Based Compensation Inventories {1} Inventories Shares outstanding (basic) Earnings per common share (basic) Equities Fair Value, Inputs, Level 1 Realized loss from securities included in beginning balance Unrealized gain (loss) on investments net of taxes of $2, ($0), $0 and ($2) Common Stock, Shares Authorized Entity Current Reporting Status Entity Common Stock, Shares Outstanding Fair Value, Measurements, Fair Value Hierarchy JP Morgan Chase Bank NA (Chase) Note Details Schedule of Inventory, Current Policies Investments {1} Investments Foreign currency translation net of taxes of $0 in all periods Shares outstanding (diluted) Common Stock, Par Value Per Share Preferred Stock, Shares Issued Total stockholders' equity Total stockholders' equity Accumulated other comprehensive income (loss) Fair Value, Inputs, Level 3 Work-in-process Finished goods Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Effect of exchange rate changes on cash CASH FLOWS FROM FINANCING ACTIVITIES: Net cash provided by (used in) investing activities Net cash provided by (used in) investing activities Changes in operating assets and liabilities: Statement of Cash Flows Common Stock, Shares Outstanding Retained earnings Current liabilities: Payment of dividends Payment of dividends Repayment of notes payable Repayment of notes payable Operating expense: Gross profit Gross profit Preferred Stock, Shares Outstanding Additional paid-in capital Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding Other intangible assets - accumulated amortization Other intangible assets - accumulated amortization Other current assets Statement of Financial Position Long-term Debt, Type Notes Total adjustments Total adjustments Accrued expenses {1} Accrued expenses Adjustments to reconcile net income to net cash provided by operating activities: Net income Net income Sales, net Common Stock, Shares Issued Trading Symbol Long-term Debt, Type [Axis] Fair Value Measurements Capital expenditures for intangible assets Capital expenditures for intangible assets Capital expenditures for property and equipment Capital expenditures for property and equipment Accrued expenses Entity Public Float Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments Net amount of accumulated unrealized gains (losses) on investments in available-for-sale securities impacting investments. Represents the difference between the fair value and cost of investments in available-for-sale securities. Tax benefit attributable to exercise of stock options Total comprehensive income Total comprehensive income Total operating expense Total operating expense Research & development TOTAL LIABILITIES TOTAL LIABILITIES Other intangible assets Document Fiscal Year Focus Entity Voluntary Filers Subsequent Events Accounts payable {1} Accounts payable Accrued interest and other receivables Accrued interest and other receivables Stock-based compensation expense Provision for (recovery of) losses on accounts receivable Selling, general and administrative Goodwill Accounts & other receivables, net Investments, available-for-sale Document Period End Date Allocated Share-based Compensation Expense Proceeds from issuance of common stock - options Deferred income taxes {1} Deferred income taxes Other comprehensive income (loss): Deferred tax liability - intangible assets Current portion of notes payable Other intangible assets, net Other intangible assets, net Property and equipment, net Amendment Flag Deferred income taxes on unrealized holding (gain) loss Statement [Table] New Accounting Pronouncements and Changes in Accounting Principles Cash paid during the period for income taxes Depreciation Unrealized gain (loss) on investments tax adjustment Foreign currency translation tax adjustment Cost of goods sold Preferred Stock, Shares Authorized Preferred Stock, Par Value Per Share Notes payable EX-101.PRE 11 utmd-20150630_pre.xml XBRL PRESENTATION EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`'B4!T?[QI0%D@$``#$1```3````6T-O;G1E;G1?5'EP97-= M+GAM;,U8RT[#,!#\E2I7U+@.4!YJ>Z%W!/B\@HD0&#AST0:T\39HS@.?-<*U*KHE5UJ,N2 MYU#H?"U#2NH#-5P$/!DLF/5/3(829"M(`^R?-(TX.0^A,Q98X2H`+T7J_$Z` MZ^+?(Q_,^39.`NJ,8VHF_*>,R-LVH MY;>,./_C6EJ;6$LQMVS#6P1U;VV*8RH95UVMVFB[>M-Z=+%V]#?[KOQ-:`_';&OS?M/ M36]`1YJA1Y,X24>&1,QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^ M.R6:E((C-Z."N[_8_`)02P,$%`````@`>)0'1[:A'7%.`0``Q0\``!H```!X M;"]?J$.Y6@4A>M&LP%.+-NKMO$8.7\PTVTP;3\F/$_VQOZ[HK\6K+UP%-^*-" M?FT@9#Q(Q8,42]`V'K1E"=K%@W8L0?MXT)XE*(L'92Q!AWC0@27H&`\ZL@2= MXD$GEB!("1E3GB0*:QZM@>`:>+P&`FS@$1L(LH'';"#0!AZU@6`;>-P&`F[@ MD1L(NH'';B#P!AZ]%:&WXM%;$7HKIK,V==CFT5L1>BL>O16AM^+16RWT]JUV M6#T'UYG&KUWS;3A9M,#;AT>/ZZ?,4\F&A=9AV@GE?%W]VYJG?H;(7W_LEP]0 M2P,$%`````@`>)0'1P5]M+-@`@``Q@<``!````!D;V-0&UL MO57=;]HP$/]7K#QMTFAHQOJ`:"06F(K4#U0H?:Q`TH,BST!D5KI-V*TP356)F0FN(*)<8<(50H7ZIRPQD5FG M7&_\ZG0I]1/>I7,SX@Z:7KN&*OJ*6X@IZ4[T6EEB+C;4IRI\HQ772XB;V/?& M+1<+L%AT>AJ<=.FK*=CJJ]C`8ZF74RXMAH/<]7,0SMC7,>7NV"G%1A1#Q\6< MZD.//7*$0CSW!PX-?*4FQBF[+L MA4&O1)"TB_3KSL)7VG;Z+C1SZ13@33+EUOTG*LJ>:B)Z7J/[;0C&=3:'C)IKB<[(: M2SNGU3YS1CQUJ`:(6;$30..!`HRC?3CE&_ZHH!5QSZVEZ[MAM]2+S=M!14WH MRJI;[;_HBK,%5QFP*^"86=B/G66/"+^SXMZ-\[VH@\R=ML^EP=P#F]$#BC,% MQ9PJPT>=/;!ASJ4JF.K0(^@@WT/9GFZW.3]?6]#]U*39EQ$X+C\>^"M0X=?/ M]QZTO\N#O0>]=VNTN0_?;#]_]Z\=_@502P,$%`````@`>)0'1P'=F$L_`0`` M:0,``!$```!D;V-0OXZ3@EG+CX,D9"PXE^*N] MJK6GW"Z2#:*EA'B^`<7\*%3HD%P;IQB&T%7$,KYE%9!QEET3!<@$0T8.P-3V MQ*0L!*?<`4/C.KS@/=[N7!UA@A.H08%&3_)13I+R16^U:71!!GU9!,#:IU!Z9YA!47E)L+2R24^?7R=W]ZB$IQUD^2[-YFMVL\CF=S.AT^GZ8[,S? M8%AU0_Q;QR>#<;LHL88+=QLU(BXW?D:0`,^=M"B-O@@7,=_$$>9W'Y_`\7)0 M)XR7;0MM8YSP9;Q?0W1X.6%EE7'M,?4C.GM5Y1=02P,$%`````@`>)0'1YE< MG",0!@``G"<``!,```!X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X M9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/`0L MZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#0 M5%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@ M?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSV MQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XYB1'^ MQL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>" M(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RC MEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNEVOZ< MTT#PE"\D^DJ1CVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-& M(81IN_`>KR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@ MR.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z& MU3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@* M-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MSAD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y M/%_GM,T+,T.WF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?! M4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D M8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2 M.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S M&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#`DL M6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R M0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[\8$@ MF_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS M#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O M#;#"Q([A[8N_`5!+`P04````"`!XE`='I88%_C@"``#G"```#0```'AL+W-T M>6QEAJ&T8A,-C*H/G0;T6V95N@%T^6 M,[N_?GIQ[#@0TF7-EB\Z/;I[[KFS?''4J)[BQPIC!3I&>1/#2JGZL^7$/@.+[F,0S"&^B]GG3I'^?5 M9P?4H:'VAAJ2J!!\7HH!DJAY`5M$M7]@W#-!A01*]TIKL`A'##N/>T1)*HD! M"\0([1V\,H!M[^#'"!?2YG89#O,L_2F3+-,8^L/O]>G2B=TNICQ"Z;P\#211 MC93"DJ_U!@SVIJ]U<5QP[$1:OQ/>I41]L+K9"["+SIL*F6,Y9@[@#DHBB@NE M`R0I*[,J41OI0BG!M)$35`J.J*'<10R&ILTPI8_F,C\5,^ZN`,['/&,?`J-B M9^I&#.9T#6Q3O7TVQ[U'>WL6+>B*D5]'H[JF_1=*2LZPT^J@M1AVI^B#(_1) MA':LH!*2O&A_<.(VYNCLRDZHB!M"56$[S0@\[_W8'33V82;)JCFS+MI>-I3A5+]U3'+HLER M7*"6JA]D*Y0]C.%D?S/R@W#TVHP4,9SL[S@G+;NU"J9/F^0W4$L#!!0````( M`'B4!T>H"`AT!`,``/8(```/````>&PO=V]R:V)O;VLN>&ULE9514^(P$(#_ M2J9/=S.GM!50&7$&`>^8460$]=$)[2(9TX1+4E!__6U:.!>ICCR1--VOR>Y' M]LRV5MH\3[5^9B^95+9EVL'@7*U.`R;-0.2.Z&5G8N%#=8T^QV:71C@J9T#N$R6L(P+%9R?V=9,2+@' M8Q',^&(QY!FT@Q<9,,FMZZ?"0=H.ZCC5*]AZ8/+%12ZDGS3"1E#SL,U11X8E M.H42-ID+^[!>"%@*,YY+-\'-;K[;#J*X'L?-DN%?NQ>PLA3H'S">.+&$"9^V M@S!@/'?Z4D@'IL<=_#8Z7PCUA*R`S82Q;NR/6[R9"24R\>;WC3,[UZL_VH@W MK1R7X\1H*8LHOU`$X1?L_R>X1R>2K1<=G][Z2K2#9HC`I;!B*J1PK^V@&$OP M)ZE].$J1_O<14T5R-B5F7*6LKQQ2V$"5QA]K=4S"CW?#ARAS)TET MCO563PC1"L<)>!$LXP1T0D`GNZ"!6F((R@R6!)V2H-/=H+'3R?,!'@%2UM49 M7A=VQ[60RA96G$`[L&S$7[FWG01N65JAZ0,WABN4_!839Y9;L53,J,),?UKK MBB31,*IA5.'A)1>&W7.9`[L&;G,#.P@J8%1AX#B?6OB;^_]I?_DQF$H755CW M9;4C:EU$M8LJO"/U?F1CO/#37(+WL%R@**I@5.$@2>8CZRRYD+Z4!WCS'%B^ M75,J851AX2<)WNR0HJB:486;7QXP#NDM1A6-*Q3]3'/VHP>."XJBTL85TF[9 MOHZ7]B=%;%VJ7[N[F^Z8WJHQ]3G^OL]EOF)ZK\;4Z[B^[DKOC0A[L5"0^C9M MB\]@GTM\[\:?\A]9;_B2^?DU]O-VX)LN]M=MJ21ONO7Y/U!+ M`P04````"`!XE`='/TF"DXP"``"1"0``&````'AL+W=O+,*3D84]<&.`S3H"--[U>EZ7OA5DZPO]M:,MN M*Q_Y0\=K^&WL3=NZ<'OV/L M33=^'E9^J,=`6[J7.@11CRO=TK;5D13YKPWZP=3&^_3KAK^C@BZ9>V? MYB!K-=K0]P[T2"ZM?&6W']3FD.B`>]8*\^OM+T*R;K#X7D?>X=GTYGF#+S&V M-K#3B=-$36$(T&%)M,860FKV]$DJKD[.:),]'_-GI62D:H M>3(QN9FIJKQ681E<=9@'!3:*#2C0J`A4;"<`^RX[-G;\-6`+BF@>$#T"H',= M&7L\;X\?[3'88V-/7.,#Q084Z3P@<0(28\\F`*#(YP&I$Y`:>S$!``4*YPF9 MDY"!'TT@K`3/(W(G(@=_](CHC20!!$BR,$V+!7-5.#$%8.*)3*PDF4>@T,DP MW2I"^G4N6ZN)LB2/P@7_"T)NE"W.S(5*;?U:35&D15+D2V#8#8-"1?G$Y`V: M8@$EW;I)1R`8^]X^UB;,SKXD%?EF9SH+\)/32^\'9/J'#;'Y9$Q214^ M?%*36JO[T=AHZ5'JUTS/-MP8H"'9>;@`C;>PZC]02P,$%`````@`>)0'1T%S M)O'.`P``01(``!@```!X;"]W;W)KMQ'0L5!=74N*>MZ^D&;FQ08^YL2[^AOHY M%'\.M3ZUW<_^X/V0_*ZKIG]<'8;A^)"F_?/!UT7_L3WZ9OQGWW9U,8R7W4O: M'SM?[.:@NDH%8R:MB[)9;=;SO>_=9MV^#E79^.]=TK_6==']O_55>WI<\=5R MXT?Y3^*>V_3E= M_+-[7+%)@Z_\\S`U48R'-Y_[JII:&I_\"QO]^\PI\/WYTOJ7N;NC_*>B]WE; M_5?NAL.HEJV2G=\7K]7PHSU]]=@'/37XW%;]_)L\O_9#6R\AJZ0N?L.Q;.;C M"?[)&(:%`P0&B',`5V2`Q`!Y%9""LKE?GXNAV*R[]I3TQV(:;?XPXMW4R-AR M,G:F'_,TM]G-F=JLWS:2K=.WJ9T+1,S(%A!QF\BQ$7Y&TO'Y01'B4@3<_"0@ M7MR/EY?Q"N(EQ,M+BA@RHTJ-"$"D"TX<&TH0Z`E&7ROA(35&)`B2&4`**4I90@E-F(M\0& ME5A08@DE@!@C""'`6!,Q-EE01P8Z,D('(,(Y2^0M7RAC]7TM+JC%@1;B5=P" M8JVBI`"4B7?C?%,)9T$I\^UQA!FA!1FN!:?4G#&N(C+#>5@/N)KBE!YD&./$ M5,L1DW$CQ458#[BD(M[-+3(?N&2"FDQGCAL=HRALNQSL4A%/VB(CC'/4I%JP MC`D6H2=LO5RAD5!Z@+'.7:]YEWH`RSBS,6_TE0GCLL;1/6,R'#9/CJY'N24&J`(<=Y,6,7L>#S ML(=R,#]%F2@R6H:+E$4-VJBS,:54V$8%>)^F;!09*C&(.!NQ\(NP@0IP/4T9 MZ,)(2XI!2F0G;IP#+TY1](L,95;[E2#D7,:]%V#F%Q&X3%2LRG-MPR8(E MZX(9'>.5G3,B8W(:]3F37NX&`'C0R)JAM!5(BL^C)L>Q+,R@1M;]F- MVF%HZWE[OV_;P8_-L(]C]PZ^V)TO M*K\?IE,[]1N^<,#%T!Z7#S;GKT:;/U!+`P04````"`!XE`='T5&XH`\"``#G M!@``&````'AL+W=O=^MB4['[AXES6E MROMH62=W?JU4OT5('FO:$KGB/>WTGQ,7+5%Z*,Y(]H*2RII:AD*,UZ@E3><7 MN9U[%47.+XHU'7T5GKRT+1&_]I3Q8><'_FWBK3G7RDR@(D>3KVI:VLF&=YZ@ MIYW_$FS+`!N)57QOZ"#O^IZ!/W#^;@9?JYV/#0-E]*A,!-'-E9:4,9.D*_\< M0__4-,;[_BW]LUVNQC\024O.?C25JC4M]KV*GLB%J3<^?*'C&A(3>.1,VJ]W MO$C%VYO%]UKR`6W3V7:`/QD>;6Y#.!K"R1#$BX9H-$1_&1"0V75](HH4N>"# M)WMB3CO8:KDP(3K9TXN1>I]LIK`[5>378AWFZ&IR'B2AE>Q!LJ`H01$%DP3I M^DZ(\!$")E]"@(B>^Z-'?PS^"/SQ(V)G)1DL`B1XA8-Y4>D0S9+$3I(82!)7 MD01(0))@C.=%I4,T2Y(X21(@63_WKYW^-?C3Y_[4Z4_!GRV<2?H_9^(0S9)D M3I(,2#8+9Y)-V[UT*"[5+,O&R;*Q$>E"E3U(HC1)%U!NHCA[3A)@)XJ=UBS. MS1]91LT3F$GU#PVZNY)ZI,`T9/ MRG134P;N81@HWM^>E>EM*WX#4$L#!!0````(`'B4!T?L*$P(4@0``$84```8 M````>&PO=V]R:W-H965T&ULC9C;;J-($(9?!?D^@3YP:,NQ M-&!&NQ9BYYK$[8,&C`=(//OV"U0UB3WE"C>Q3;ZJKK\:^F]Z=:F;G^W! MVL[[796G]FEQZ+KSTO?;EX.MBO:Q/MM3_Y]=W51%U_]L]GY[;FRQ'8.JTI=! M$/E5<3PMUJOQVK=FO:I?N_)XLM\:KWVMJJ+Y+[5E?7E:B(6[\/VX/W3#!7^] M\J>X[;&RI_98G[S&[IX67\0REVI`1N+?H[VT'[Y[0_'/=?US^/'W]FD1##78 MTKYT0XJB_WBSF2W+(5,_\B],^C[F$/CQN\O^=93;E_]R^UY?_K*H(1P2OM1E._[U7E[;KJY3R-GQ?X3Q)@&!T@ M,4!.`=,X=(#"`/4>H-D`C0%Z[@@A!H0W(_B@?>S*8@//X_7U_$:XC7$1]C.D!$AHP@8:<@5``4AHV8\C2(@!8V7>T5,;U-DI%#<-#E* M)LRSO4%*JXBA9A3X9PZ8*ALHKB%82.<4W.Y).0NB MH/UT,K#VA!DG1::OF9Q9IVRBR&?6 M*8O_K)E0-E'Q#&7TGD.`Q1MNTX&,BD-FG*78%F2AFG5T3L/`5Y/ M;^*=,H/CW+Y_72N;*&[[,8O*WZD9=Z.\V8+@/E."V9L9JZNDK5Z"J1I2-:Y! MR$@5,2\X&5))2#X:N`0A]"#HUN`2A)008L:D2]KI)9BJX9Q>DN^R5S.."'G4N M]O:?HMD?3ZWW7'==78TG,+NZ[FQ?)0'1W]<,YT)`@``*08``!@```!X;"]W;W)K M20JJDY9,X" MVDN-9#F2P)._CQ9C,#$X%V2UWWO]NH7::E-O8JLI0?%:UJ>!5('ADC MXL\**&^77N"=`V]542H3P%F*>]ZA8E#+BM=(0+[T7H+%-C$("_A502NOGI'Q MON/\PVQ^'):>;RP`A;TR"D0O)U@#I49()_[=:5Y2&N+U\UG]FZU6N]\1"6M. MWZN#*K59WT,'R,F1JC?>?H>N!.MPSZFTOVA_E(JS,\5#C'RZM:KMVKHWSWY' M&R>$'2'L"7V><4+4$:(+(7Y(B#M"_+\9DHZ0W&3`KG;;N0U1)$L%;Y%LB/D[ M!0L-%T9$*R/=+JE/PFH*>Q99>LJ^SE)\,CH#2&@A*P>91_@36^4=- MA-Y8AM#2P_L)U@XQCQ]XF!39_B-RUV8TM!FY7D6.GTSSXR$_=OS8]7H^M%A; MR,QUPD'\^XCU)&(SB=C>(N[6D8S6D;@ZGA_4D8P=QJ".9+*.2<36(;Z$-X7@ MJXO`0!1V!$FTY\=:N;/MH_V4>PG-1;J)KX+%.AB);_14=$/L(I^E#2G@)Q%% M54NTXTI?7WO+=VOZ&0*_,X-\UVH\QM%&_.@[G_.F1_`5!+ M`P04````"`!XE`='S\63EU0$``#1%0``&````'AL+W=OD/K"2ZDAQO M_WTE<:@XR63"2VPK#X?O4.0[)-(HT]_XM!7_N< M&MY_=]%_G],=Y3]7O2Y-_<]Y/YQ&M?$JV.M#=:V''^;VA\8Y-L>[,,G:07&\=$>)2.'SBFB?%-;A$K(..B%HE*EB1\52F?+00KNE0"L4S+3<.HA37"($ ML8\L^?/0P"=$;J=X&HB0B%K M(*6C<`=)Q`*"\4-ST))CWDC:?N4:)_`V2="H4H39GJ5#I.) MSP%6T@8JI3M*<8*6K2%%PHI3QJA*1-6:(I2W+5X'T,0BDY>_`ZQ@5*WQ?/Z.ZFK-'=<;Y![(.= MN;:#O<9:GBZWE$\PW;2]>[X5#Z6]:WP-LUE?JJ/^J^J.Y[8/GLTPF&:^;CL8 M,^A15_QM'*R3KO;+CUH?ANEK-HVBO7&T/P9S<1>HRRWNYG]02P,$%`````@` M>)0'1^88=-VB`0``L0,``!@```!X;"]W;W)K;$#@".O2FI[H(-SXYXQVPR@N+W#$;3_TZ%1W/G4],R.!G@; M24JR(LL^,,6%IG45:T^FKG!R4FAX,L1.2G'S^P@2YP/-Z5IX%OW@0H'5%=MX MK5"@K4!-#'0'^I#OC[N`B(`?`F9[$9/@_83X$I)O[8%FP0)(:%Q0X'XYPR-( M&81\XU^+YEO+0+R,5_4O<5KO_L0M/*+\*5HW>+,9)2UT?)+N&>>OL(QP'P0; ME#9^23-9AVJE4*+X:UJ%CNN<_A3%0KM-*!9"L1$^9=%X:A1M?N:.UY7!F=B1 MA[/+]QYN@HA7)MZ;]6-'31,'KZMSG9=YQ5R/OX3LWO="6G-#YDXT'T"$Z\.VSNWM*!O]^MD1"YT+XT<&PO M=V]R:W-H965T&ULC5/+;MLP$/P5@A\0RK*<%(8L($Y1M(<" M00[MF996$A&2JY*4E?Y]^9`4.S#:7L3=U*"TVK,M:>357BZ*30\&R( M'97BYO<1)$X'NJ%+X45TO0L%5I5LY35"@;8"-3'0'NCC9G\L`B("?@B8[$5, M@O<3XFM(OC4'F@4+(*%V08'[Y0Q/(&40\HU_S9KO+0/Q,E[4O\1IO?L3M_"$ M\J=H7._-9I0TT/)1NA>T"AW7*?VY?YAI MMPGY3,A7PJ:3G_Z9OK^G;Y'`[._P/@>):H$@"Q=]& M3)CC@ME]:,(N]E2!Z>+5L:3&4;NTI6MUO9V/>3R3=WA5#KR#[]QT0EMR0N=/ M-AY`B^C`M\_N=I3T_OVLB836A?#!QR9=J90X')8'LK[2Z@]02P,$%`````@` M>)0'1]DW,9JD`0``KP,``!@```!X;"]W;W)K MQ-W5S.PL']6,YM4.`(Z\*ZGMG@[.C3O&;#.`XO8.1]#^3X=&<>=3TS,[&N!M M)"G)\BS;,L6%IG45:\^FKG!R4FAX-L1.2G'SZP`2YSW=T'/A1?2#"P565VSE MM4*!M@(U,=#MZ<-F=R@#(@)^")CM14R"]R/B:TB^M7N:!0L@H7%!@?OE!(\@ M91#RC=\6S8^6@7@9G]6_Q&F]^R.W\(CRIVC=X,UFE+30\4FZ%YR_PC+"?1!L M4-KX)&D6;3]SQNC(X$SOR M<':;G8>;(.*5B?=F_=A1T\3!Z^I4%]N*G8+.%23Q#@FR61',B]_LD--;]#S2 M\W_3BVMZD0P6J7OQ'P+EM4"9!,J_3)@@AW+IL?VC![O8406FCQ?'D@8G[=*& MKM7U;C[$(V0?\+H:>0_?N>F%MN2(SI]KW/X.T8%OG]W=4S+XU[,F$CH7PD\^ M-NE"I<3A>'X>ZQNM?P-02P,$%`````@`>)0'1ZGTU]VB`0``L0,``!D```!X M;"]W;W)K&ULC5/;3N,P$/T5RQ^`T[0LJ$HC459H M>4!"/.P^N\DDL;`]P78:]N_7ER2TJ()]B6#;$#DIQ\WA[-;;3W.FB8.7A;' MI84N&@7=K2I;K.-CDZY42ASV\P-97FGY#U!+`P04```` M"`!XE`='M>@2SJ,!``"Q`P``&0```'AL+W=O=3TS$[ M&.!-)"G)\BS[QA07FE9EK#V:JL312:'AT1`[*L7-GQU(G+9T18^%)]'U+A18 M5;*%UP@%V@K4Q$"[I7>KS:X(B`AX%C#9DY@$[WO$UY#\:K8T"Q9`0NV"`O?+ M`>Y!RB#D&[_-FA\M`_$T/JK_B--Z]WMNX1[EBVA<[\UFE#30\E&Z)YQ^PCS" M=1"L4=KX)?5H':HCA1+%W],J=%RG^4\QTRX3\IF0+X2;+!I/C:+-!^YX51J< MB!UX.+O5QL--$/'*Q'NS?NRH:>+@57FH5NO;DAV"T!DF$7)_(R;,;L84V3]-V,F>*C!=O#J6U#AJ ME[9TJ2ZW\RZ/9_(!K\J!=_";FTYH2_;H_,G&`V@1'?CVV=4U);U_/TLBH74A M_.YCDZY42AP.QP>RO-+J+U!+`P04````"`!XE`='E?GIQ*(!``"Q`P``&0`` M`'AL+W=O;4#@"-O2FI[ MH(-SXYXQVPR@N+W#$;3_TZ%1W/G4],R.!G@;24JR(LL^,,6%IG45:\^FKG!R M4FAX-L1.2G'SZP@2YP/-Z5IX$?W@0H'5%=MXK5"@K4!-#'0'^ICOCV5`1,!W M`;.]B$GP?D)\# M_CPLM-N$8B$4&^%C%HVG1M'F)^YX71F9E7[!R$KC")>%PP&X)Y]9LM"GJ+7D1Z\6_Z[IJ^2PYWJ?ON/P3*:X$R M"91_&S%ACBOFSR;L8D\5F#Y>'4L:G+1+6[I5M]OY6,0S>8?7U@++[%H@$``+$#```9````>&PO=V]R:W-H965TU#I2@/[;,7!K!B>ZAMEO3OZPN0 MW6C5]@7/#.><.>-+-:-YL0.`(Z]*:GN@@W/CGC';#*"XO<,1M/_3H5'<^=3T MS(X&>!M)2K(\RSXPQ86F=15K3Z:N<')2:'@RQ$Y*!FOZE_BM-[]B5MX1/E3M&[P9C-*6NCX)-TSSE]A M&>$^"#8H;?R29K(.U4JA1/'7M`H=UWGYDR^TVX1$>0;X5,6C:=&T>9G[GA= M&9R)'7DXN]W>PTT0\[-^[*AIXN!U=:YW95&QZK`]/'J6-+@ MI%W:TJVZW(CL#5Y7(^_A.S>]T):TH&_WZV1$+G M0OC1QR9=J90X'-<'LKW2^@]02P,$%`````@`>)0'1P\-2"2D`0``L0,``!D` M``!X;"]W;W)K&ULC5/+;MLP$/P5@A\0RK*<%H8L M($Y0M(<"00[MF996$A&2JY"4E?Y]^9`4NS#:7L3=U*"TVK,M:>357B MZ*30\&R('97BYM<1)$X'NJ%+X45TO0L%5I5LY35"@;8"-3'0'NC#9G\L`B(" M?@B8[$5,@O<3XFM(OC4'F@4+(*%V08'[Y0R/(&40\HW?9LV/EH%X&2_J7^*T MWOV)6WA$^5,TKO=F,TH::/DHW0M.7V$>81<$:Y0V?DD]6H=JH5"B^'M:A8[K ME/[DQ4R[3&H4;3YQQZO2X$3LP,/9;?8>;H*(5R;>F_5C1TT3 M!Z_*<[4I=B4[!Z$K3"(>9\R*8%[]9HN): MH$@"Q=]&3)CC@KG_HPF[V%,%IHM7QY(:1^W2EJ[5]78^Y/%,/N!5.?`.OG/3 M"6W)"9T_V7@`+:(#WSZ[VU'2^_>S)A):%$//C;I2J7$X;`\D/655K\!4$L# M!!0````(`'B4!T=\K`T5H@$``+$#```9````>&PO=V]R:W-H965T&,"*[2&V6=*_ MKR]`=J-5VQ<\,YS+C"_EA.;5]@".O"NI[9[VS@T[QFS=@^+V!@?0_D^+1G'G M4],Q.QC@320IR?(L^\(4%YI69:P]FZK$T4FAX=D0.RK%S>\#2)SV=$.7PHOH M>A<*K"K9RFN$`FT%:F*@W=.'S>Y0!$0$_!0PV;.8A-Z/B*\A^=[L:19:``FU M"PK<+R=X!"F#D#=^FS4_+`/Q/%[4G^*TOOLCM_"(\I=H7.^;S2AIH.6C="\X M?8-YA-L@6*.T\4OJT3I4"X42Q=_3*G1)[LW[LJ&GBX%5YJC;%7@"DXB'&;,BF%>_ M:I'3:_0\TO-_T[>7]&WJ<)O?3-C9GBHP7;PZ MEM0X:I>V=*VNM_,ACV?R`:_*@7?P@YM.:$N.Z/S)Q@-H$1UX^^SFEI+>OY\U MD="Z$-[YV*0KE1*'P_)`UE=:_0%02P,$%`````@`>)0'1QUD_1FB`0``L0,` M`!D```!X;"]W;W)K&ULA5/;;J,P$/T5RQ]0`R'= MW8@@-5U5[<-*51]VGQT8P*K-L+8)[=_7%Z!)%:DO>&8XY\P97XH)]:OI`"QY M4[(W>]I9.^P8,U4'BIL;'*!W?QK4BEN7ZI:900.O`TE)EB7)+5-<]+0L0NU9 MEP6.5HH>GC4QHU)B.P)QJ:/;U+=X?< M(P+@KX#)G,7$>S\BOOKDJ=[3Q%L`"97U"MPM)[@'*;V0:_Q_UOQLZ8GG\:+^ M$*9U[H_L4)KP)=5H+*J%0HGB;W$5 M?5BG^.=G,M.N$[*9D'TAL-@HV/S-+2\+C1,Q`_=GE^X<7'L1ITR<-^/&#IHZ M#%X6IS+-?Q7LY(4N,)%XF#$K@CGUJRTR>HV>!7KV/7US2=]$AYO8?9M\+Y!? M"N11()\%TFLC1LQAP7QUR<[V5(%NP]4QI,*QMW%+U^IZ.^^R<":?\+(8>`M_ MN&Y%;\@1K3O9<``-H@77/KG94M*Y][,F$AKKPQ\NUO%*Q<3BL#R0]966'U!+ M`P04````"`!XE`='\!::K*4!``"Q`P``&0```'AL+W=OFS=]95B9,5@X)G3,TA09D!%-+0'^K#;'W./"(`_`\SF(B;>^PGQU2>_F@--O`40 M4%NOP-URAD<0P@NYQF^+YD=+3[R,5_4?85KG_L0-/*+X.S2V=V832AIH^23L M"\X_81FA\((U"A.^I)Z,1;E2*)'\/:Z#"NL<_Q390KM-2!="NA&^)\%X;!1L M/G'+JU+C3,S(_=GM]@ZNO8A3)LZ;<6,'31T&K\ISM2NRDIV]T!4F$H\+9D,P MIWZS14IOT=-`3[^F9]?T+#K,%H?YUP+YM4`>!?)%H+@U8L0<5\S]IR;L8D\E MZ"Y<'4-JG)2-6[I5M]OYD(8S^8!7Y<@[^,UU-RA#3FC=R88#:!$MN/;)74%) M[][/E@AHK0^_N5C'*Q43B^/Z0+976OT'4$L#!!0````(`'B4!T>XN`IAI@$` M`+$#```9````>&PO=V]R:W-H965T6CG-"\ MVA[`D3U#95^8XD+3 MJHRU9U.5.#HI-#P;8D>EN/EW!(G3@6[H4G@17>]"@54E6WF-4*"M0$T,M`?Z MN-D?BX"(@-\")GL1D^#]A/@:DI_-@6;!`DBH75#@?CG#$T@9A'SCO[/F>\M` MO(P7]>]Q6N_^Q"T\H?PC&M=[LQDE#;1\E.X%IQ\PC[`+@C5*&[^D'JU#M5`H M4?PMK4+'=4I_=OE,NTW(9T*^$AZR:#PUBC:_<<>KTN!$[,##V6WV'FZ"B%ORG.UV=V7[!R$KC")>)PQ*X)Y]9LMTW?)H?; MV6'QN4!Q+5`D@6(6>+@U8L(<%\S7#TW8Q9XJ,%V\.I;4.&J7MG2MKK?S,1XB M>X=7Y<`[^,5-)[0E)W3^9.,!M(@.?/OL;D=)[]_/FDAH70CO?6S2E4J)PV%Y M(.LKK?X#4$L#!!0````(`'B4!T>2Q5Y>H@$``+$#```9````>&PO=V]R:W-H M965TK#[K,# M`UBU&=8VH?OW]05H4D7J"YX9SCESQI=B0OUN.@!+/I3LS9YVU@X[QDS5@>+F M!@?HW9\&M>+6I;IE9M#`ZT!2DF5)I[M#[A$!\$?`9,YBXKT?$=]] M\ESO:>(M@(3*>@7NEA,\@)1>R#7^-VM^M?3$\WA1?PS3.O=';N`!Y5]1V\Z9 M32BIH>&CM&\X/<$\PM8+5BA-^))J-!;50J%$\8^XBCZL4_QSE\RTZX1L)F3? M""PV"C9_<\O+0N-$S,#]V:4[!]=>Q"D3Y\VXL8.F#H.7Q:E,;Y."G;S0!282 M#S-F13"G?K5%1J_1LT#/?J9O+NF;Z'`3NV_SGP7R2X$\"N3SB.FU$2/FL&"^ MNV1G>ZI`M^'J&%+AV-NXI6MUO9WW63B3+WA9#+R%%ZY;T1MR1.M.-AQ`@VC! MM4]NMI1T[OVLB83&^O"7BW6\4C&Q."P/9'VEY2=02P,$%`````@`>)0'1^!6 MX*?A`0``4@4``!D```!X;"]W;W)K&ULA93+;J,P M&(5?Q>(!:NZD$4%JJ:J9Q4A5%S-K)_P$5!M3VPF=MQ_?PB0523;XPCG'WX^Q MRXF+#]D!*/3%Z"`W0:?4N,98[CI@1#[P$0;]IN6"$:6'8H_E*(`TUL0HCL,P MQXST0U"5=NY-5"4_*-H/\":0/#!&Q-]GH'S:!%%PFGCO]YTR$[@J\>QK>@:# M[/F`!+2;X"E:U[E16,'O'B9YUD>&?;T3]^H3L.&`6J@)0>JWOGT`WP)F0G<<2KM M$^T.4G%VL@2(D2_7]H-M)_>F>/2V94/L#?%LB-*;AL0;DF\&[,AL72]$D:H4 M?$)R)&:SH[66"Q.BDY$N1NKO9#.%_5)5>:RB/"GQT01=:&*K>7::^+JB=HHD MFB58`RQ2Q)<4;O(I]A3I_8#D,B!U`8D/R"XA!ZO)71E>DV7I=5'M1:NTN(^2 M+J*D'B5?6B5S*%X3A=%U43V+DOLHV2)*YE&*&RA>LXI6-U"\Z#&.[Z/DBRBY M1UE4JJ)7JEAC+H@9&Y!/OH-5O*BX84?HH#EAV`DAI28SB.`SGF)&F M#?+,QMY$GO&CHDT+;P+)(V-$_%T#Y?TJB((A\-X<:F4".,_PR"L;!JUL>(L$ M5*O@.5KN4H.P@%\-]/)BCXSW/>R)AP^GOIE2U-AL&J(2*'*EZY_TK^!)F1K#@5-HG*HY2 M<390`L3(IUN;UJZ]>S,//6V:$'M"/!+&/-.$Q!.2,R%]2$@](?UJAIDGS&XR M8%>[[=R6*))G@O=(=L1_7%P32:X'4":2^C!N3K<7,73L<)GX`V7B9;_JL?_WFP$``.,#```9````>&PO=V]R:W-H965T'1(T<2TNGJ;V85/6BNR;Q[QB5@P[P"D\+;^S4 M6[]`FIK,O)8)D(8IB31T._QMM=U7'A$`[PQ&@',OY(Q_)\V_EIYX/9_4?X1N7?H#-?"D^"_6VMZ%S3!JH:-G;M_4 M^`RIA9#PJ+@)7W0\&ZO$1,%(T,\X,AG&,>X4CXFV3,@3(9\)>0P>C4+,[]32 MIM9J1&:@_NQ66P?77L0I(Y?-N+:#I@Z--_6E66V*FER\T`TF$O<3IIPQQ.DO MFN2W)F4TR9-`=5^@6!0HDL#Z-J4,F'5,F3!EEF7W;VK,#$T!K8VH[8?OOZP]"DA6;Y!+;PWMOWHSE239P\2X;`(4^&.WDVFN4 MZE<8R[(!1N03[Z'37_9<,*+T4=18]@)(94F,XM#WEYB1MO/RS,9>19[Q@Z)M M!Z\"R0-C1/S;`N7#V@N\4^"MK1ME`CC/\,2K6@:=;'F'!.S7WB98%:E!6,#O M%@9YL4?&^X[S=W/X6:T]WU@`"J4R"D0O1RB`4B.D$_\=-<\I#?%R?U)_MM5J M]SLBH>#T3UNI1IOU/53!GARH>N/#"XPEQ$:PY%3:7U0>I.+L1/$0(Q]N;3N[ M#NY+ZH^T>4(X$L*),.69)RQ&PN),B&RESIFMZP=1),\$'Y#LB;GL8*7APHAH M9:2+D;I/5E/83N79,0^2-,-'(W2%"2UFZS#)8H)@+3^;(_3F^*'EAU]G*!PB MB>YG6%QG<,'-PE6Q?$`@NA:(G$`TMN'[M&PO=V]R:W-H965T MM-=.&`): M&[.V$[9O7Y]"$\E:T'>!5(GADCXN\> M*)]VT2JZ+KSUITZ9!5Q7>*YK>@:#[/F`!+2[Z-MJNR]-ADWXW<,D;^;(>#]P M_FZ"G\TNBHT%H'!4AD#T<(%GH-2`M/"'9_Z7-(6W\RO]Q7:KW1^(A&=.__2- MZK39.$(-M.1,U1N??H!O(37`(Z?2/M'Q+!5GUY((,?+IQGZPX^3>%+$O"QK;8Z71B()B/M3>JV+5/8QNOJ4J^*=84O M!G27XPKW/B??S#E8\X,BR;W(QHDD7N0!P#H(6'M`>N]RL#F9<^ERTG)98Q/4 MV'B-;!F0!@'I5R939]+EQ,L265`B\Q+Y,B`/`O('/.:/>BR"$H67*)8!91!0 M/K#997BS\)#ESITV1_^I9S!1H1/^EV.WUGS0&%5IEI;KZ# M.\8N4'R\7DKSS5C_`U!+`P04````"`!XE`='HFGS`E00``"R/```%````'AL M+W-H87)E9%-T&UL[5OK98EKP\/=3`7"ZX/5")B/)FJ=,$S_)K.#G62"A[J MN1#9(CH\[G9?'"ZXC/=8'LM?<]%7>9Q]NW=T]FKO[1LMW[[)WIZK(%^(.&,\ M#MD@SF2V9,/8RI0J9OOL?G3.6L_:;PZSMV\.:9*=^()=J3B;:TP*1;CY]!]Y M?,!.NAUVW#UZOOFPE\\.6/=%_<,G%'J].=X-N1,SJ;.48^(U7XC-4??CWO?L M:G`^[/W=S?E]?SQBP^M^X_+C9>)).>KNOV^<<"M2J4CED)WSS)M;6.1O M7WU5:Q/("(V:0]B6[G?4Q*>00CA>(C^T$L-\?U\S0U@J4.,.YG MP=-&+??WCX[W3XZ:EE*+!6)BE*G@0X>-YCP5FMWDF<[@+!E[:KMIM_DDD@$V MIGC6,.1"1B)E?6@T4ZFW@UX0"#S'T]".;-+/[?1.)"K-H!!4Y5FN-X?_++R/ MG(0?5804X:G3R!MVK1HF_B2B:/]#K!YA'L&UBJ'J4.OTM8F28>RY(#U;ZY'-Y?#\]YX<,[> M]2Y[U_T!&WT_&(Q7$,&>,1FS\5SE&O'@;T<$R(`CD_:G34'*M1:9]K*\S_5\ M\[-A_"!T1@;2'<8?N(SX)!+[@(I]S2,OM!%$!'^:_9TODF^8RN:(N%0$0C[0 M/,B(A1>>M$:GL^4!G\MGW,;0H@3Q%"!'CBUUPFM*5:;;Y3 M*GR4D>=,JXI$X,8SB;TTK-0P#`[D`2(MCTR"\07ESF\&;7>44*OL^&:,,.J- M1H/QJ,G;D>03&^XB/JH/;]4ZQAH`"HI:8L5IEH ME+?NJXIF/@9LD7(NI@(20I;QCZ60)4S\I'?*F3(.U$*0`']M:]3+8>_=\'(X M'@X\RQILGJLH!'A];<(I6WJFO4V+M30-AW;/#KI'V%+*'GB4BV\8S[,YHOXW M#-EGSSO=;I=I`_??P(CN1R8)WT*F4J:::X"K&;LMU%U;R?G\9:$$90V012PFB,P"7QK!,`SKH&H\]Z7;6NSYGH_%- M_X?O;R[/!W>CK]G@_?UP_/-?A.FM6TYI,!>91.5ID^/886'RPOU;L)[JKC"U M"VEW(6,>!Y(JF-*R#E=6`>FX!99G/U*$4-&S3./).8Z/],J(VG6&J=,[C][" M=];YT0Y[J"54S1NH'5ZO_>=2M9WC9#3&MZO!]9C=7-#CFZM!A0'4A$;G"5IP MLG,CX9&&H4W4,MB\*.1-=;VOM`G-&2HJ`AK9Y]7:%-G/DE1-I3?[)B$R2N3* M%1\/84>@@WC>83,1"V+G!%,\7,C8="D98,:'"PV@".:.GX3B040JJ=N6Q0VU MJ42SEA;0FHJY!3LGQ,,[9^.)`*\29(\'J:FME>IVYY'7(FO0<."`DR46 MHTTAH0ACK0G7,O"4W3(AE%$.P/>FN-2H5+`FX74CFZ3>/%56O(BY@'GE+'8$ M)%@R:F9U9+MP1#!%JS$?_?"L2RG%HX@VBI[`L^E]G`H>F;(Z0Q%RBS*(DBO6 M[(L][B"+N^T.+4`1VWIV[&W-\:2:K?VEF.)7H-VZC*UV)%+&PU]R:X`_9K0G M9.RZ9_QR/K@>;>Z^WQM]SRXN;W[:>W@[O>>'C]'>OUQ\,? M#5WPR76Y`6Q(41ND4*'!3>,R&>ES^BU`ZV7S'O#,)LL*\/``0%;/WL\%P@,U MOZ[:][9T&.NPT2+%'@3:<35M,W('!6I,_8KM#5;]VZ:@UG=PH9U#,T*I$Z4) M-J<-_-N4RGVD/G9)T8W0MD'3`*_].?B\K745B]B.BG)GI]ZF6?^BO4'?(``[ M]CS,:UIK2`NQTK(IJLS:I5-=Q74M2N\4"D_%Y_#ZQ\'HJ?CL6TIM]P'"G1/R M4D0DM=WRSM.?[,)JM]G*M?%$VP'!YVWX8G@-9OW$AA'W@1#@(M-4+4SG`\HL M*%J#]09*)124_J+544D.'F$"F:R4`D+3&G[+EP5!MP6`[",^!B:LZ5,KJV&] M,5!P`FX#=L1XEJ5RDF<4D80:XJ-(`ZF?%G*'8"V5V-J<5Y0-)?FE!@B?<-W4 M=B%;73>83D5@5BD-0:>.+'"YKF*S0@.#0?70Q#2$_8FBQ2I$7C`_4,"B\:W+ MK[X9F,&H,QD3B2$M;'5O&BHHM[<.,E@0YBF)`PBXH4\RLJ?G6DS:G/<.O,D0 M"<"0QB9K$=XT M8<1+97L:-3Z"9$2=X&86RO(O>6RVL=I;K6D*976QJ]6J&9^S*Q%* MX7!4YU%FXMO5/2AQX"X=0#3YPM9T:C>,Z1UA(RQ!&%`"[=MFI!P)J8^HS<)X M+CSP<>61]58Q!M_%^#FH>+Q"0M8&%L&X(9%N$E_KA`?BV[V$KQ\D0PFP.=T">A!28*PC0& MHC2L]PP+%8K(%AVZ0@$:DVL`UT5*NP5H1(IF.,YAN%1J\QD52<0`N#UBV69& M`&<#T5)K&)W#W(!^2%U0KU^PGT(2$V^TMB^1V"_\F2E6PZU`D$G6'YIMV98I,*D\G ML']RE`RLA5;[)#O%+ICL:JF81H(L0I),CH0N4&GFXUP&%D&<2D2/`ML!3-R' MD<6-LOS97%?PBJ?,AB%XI%6!CO#!ZIATA9Z,3Q`51H.8$RGK..V!!W)A@T,WE=^KXHHM-(/>J-4'`V6<5$U9<:_2"YD"Z'?\G#V2I]@E7ZK#]P M/+YT5EB$G+:HE-LS?L6F>325A$[ET@?VUIKBV90K"X+%%41NE!;24').TPFR MLE11G-&Q$%F84W)`8Q%N/.,)N`V'$PL(YN%*M#$KDE.[Q"7_(#I+!TT$57S` MD2$Y)(ZDK.&\J63V1*%"1/@4Y7X%\70$#RAX82DX)_PLUL](E1K]PSU-PO,51X1%B:?J@@!B>V\WICOS[V@X[\Y M'2^87'K&CCK/GY^:[V>G+]E/*OVP+^/]A'H!M*U'G:/ND?EZPN[X(^HG_(`= MTY.SHS-\?75\S&SG]HR==DY?GICO9R^]RV#;W+XS0-6O-+>>44[;K&GL`>ME MFUYN]/#KK6-MLM:"]';RM;6,:RN_S-EN;Y0HNG07#RD?K5E83=ZO$V3.48[HO MBQ3*@,&G?]Q>J72&W_K4_K%W//[08=<'O0,+:IAQW'EU MB$F:$P>CX/$S\B>>4@C0RSS&-%YPOFBSS3%KKK>:32*;9(_%4*E?LT__-D#D M/M,&3Q+'A4U558;X%\>J1:H1Z2MKI#EO+<6[V:P@")8/FN+INDA+"`BN3%3/ MBYM]\H4MN=-4".N'4$S-,IA>KFWH(3`!O)DF6[@N^C"#/I).0EHGW3966;J` MSY,DDG3M027B$0LN]Z<#.5\U?:4NWNC$F MR&P4=0@XR9HV7SM422).?`#!6EH8Y.?11+V*H`0'`T_[]+M5D]Z`HYPA)EKN MPV4?B73'!=8HZ"D6IK[84N]P"M$02?,<_&GI>FHL0)6*FKAR%T'$Y<*" M(0TOM+?55'QT'5(Y7"%V9RY.38K*11%L';*S9QWB]`L>&C_XY0SV6BL'7O]2 M>4/'R^67MOJZQP?53B8S!P'E63S=C9M.`SX\+,YS5R?RX*/PAR5<_EM`KG,C MF9^A-+.S8X1?_:PF8>S>T,]SH8-46N)J651E/"+^Q>%)]]!X]WU. M_3GUU4'1;!MX0I'^(!S3&(;40%%Z]FSST+JD*UQV!$95:4#LS>#-A!+,X-\P M3O+5Z./UT?>Q:AIYPMIL0,XEG\+FKXHOY(&N1P!SR/DU)Z,,'FIL7T]-6.L5 M]-F_>2Q8//TJV0ZR/7EQ./+R<>7TX\ MOIQX_/^>>&QYE_DU&P7H8?+(,/[BP;)3OD'?&IOK9?_E#_/Q83';OT3?*G:W MFO._>XI2(:RO6<_GFJ,5R6HRX-99N]GG"^7\$Y1S/?)7@SH%:Z,4OUR]NE%, M-M7NKKQ;LC>=34[^ZY;8+2*^T-P_A''G]()VI'=_M\Q-\$)M#9"\4ZUU//+> M@:A"4NU;.;N>Y?Z!#<&QY9_D>!E4?>B]>MM#`Q:8LF1>BW1'OFOJ#.K?FUH[ MZJSHO%W3M3\H;/B3Q(VS3'/\R:Y[K&5^M8>LODLG&8*#7A:P9V$7=';5,QSM M*?GK1Z5UTC^G8'RV\TIY=#7/1AOR+&!77FFD]^&@,CZL_OU#%.-?XRG-GZ@: MGU7X.@WJMB[K_@3C#]:1_TJ%V#&\J\M8_.LPAZO>.TH.#'<7X?&8YJ$GVX96 MK=19;74UY5#K[.U_`%!+`0(4`Q0````(`'B4!T?[QI0%D@$``#$1```3```` M``````````"``0````!;0V]N=&5N=%]4>7!E&UL4$L!`A0#%`````@` M>)0'1TAU!>[%````*P(```L``````````````(`!PP$``%]R96QS+RYR96QS M4$L!`A0#%`````@`>)0'1[:A'7%.`0``Q0\``!H``````````````(`!L0(` M`'AL+U]R96QS+W=O)0'1P5] MM+-@`@``Q@<``!```````````````(`!-P0``&1O8U!R;W!S+V%P<"YX;6Q0 M2P$"%`,4````"`!XE`='`=V82S\!``!I`P``$0``````````````@`'%!@`` M9&]C4')O<',O8V]R92YX;6Q02P$"%`,4````"`!XE`='F5R<(Q`&``"<)P`` M$P``````````````@`$S"```>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(4`Q0` M```(`'B4!T>EA@7^.`(``.<(```-``````````````"``70.``!X;"]S='EL M97,N>&UL4$L!`A0#%`````@`>)0'1Z@("'0$`P``]@@```\````````````` M`(`!UQ```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`>)0'1]%1 MN*`/`@``YP8``!@``````````````(`!SAH``'AL+W=OI]-?=H@$` M`+$#```9``````````````"``>\M``!X;"]W;W)K&UL4$L!`A0#%`````@`>)0'1[7H$LZC`0``L0,``!D``````````````(`! MR"\``'AL+W=O&PO=V]R:W-H965T@++[%H@$``+$#```9```````` M``````"``7LS``!X;"]W;W)K&UL4$L!`A0#%``` M``@`>)0'1P\-2"2D`0``L0,``!D``````````````(`!5#4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`>)0'1_`6FJRE M`0``L0,``!D``````````````(`!X3H``'AL+W=O2Q5Y>H@$``+$#```9``````````````"``9H^``!X;"]W;W)K&UL4$L!`A0#%`````@`>)0'1^!6X*?A`0``4@4``!D````` M`````````(`!JL?_WFP$``.,# M```9``````````````"``;A$``!X;"]W;W)K&UL M4$L!`A0#%`````@`>)0'1T6;#?P(`@``$`8``!D``````````````(`!BD8` M`'AL+W=O&PO=V]R:W-H965TB:?,"5!```+(\```4```````````` M``"``<)*``!X;"]S:&%R9613=')I;F=S+GAM;%!+!08`````(0`A`-D(``!( %6P`````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R9.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2015

Notes

Inventories

(3) Inventories at June 30, 2015 and December 31, 2014 consisted of the following:

		June 30, 2015		December 31, 2014
Finished goods	$	1,554	$	1,847
Work-in-process		1,101		1,103
Raw materials		1,818		1,922
Total	$	4,473	$	4,872

XML 15 R8.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements and Changes in Accounting Principles	6 Months Ended
Jun. 30, 2015
Notes
New Accounting Pronouncements and Changes in Accounting Principles	(2) Recent Accounting Standards. In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

New Accounting Pronouncements and Changes in Accounting Principles

6 Months Ended

Jun. 30, 2015

Notes

New Accounting Pronouncements and Changes in Accounting Principles

(2) Recent Accounting Standards.

In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Direct Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Indirect Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.10-01.(b)(6))

-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Accounting Change

-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Retrospective Application

-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 01

-Paragraph b

-Subparagraph 6

-Article 10

+ Details

ZIP 16 0001096906-15-000860-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001096906-15-000860-xbrl.zip M4$L#!!0````(`$"%!T<8O-LU;"(``+N2`0`1`!P`=71M9"TR,#$U,#8S,"YX M;6Q55`D``Q@8Q548&,55=7@+``$$)0X```0Y`0``[%WK<^,VDO]\5W7_`[8V M%<]463(I42]/9KB?__BO__SF;ZT6NN7,\DQBHL2.;'#& M%DO/)1Q=.0Y[Q"YP$,?PPVP?P[/EBM/9W$5OSMZBCJ8-6QU-[Z'_N;W]U_B_ MSR][#]__]*UQ_GIS(+O)IF_'9B>7R$W>U)"?0J`6M"*?FD=\OO0-`ZIY01[A2 MEJ#EJ2=:,XR7FQY3+":J=?``>NE&2]-;77W=11*TZ*9'F'[_Q'^X;FJ16#M! MS/:,/9[`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`EGO$^DCQ MA-K4I:3JC&\8FAYGGDZY`?[)-$XWAA6X7S.7U!SJ$,\4:K6X)>>'XDRD! MP:T'_!Q2QCKB0J(7#\SQW^7'?!`-P+41'%">Y%JW-]0/+LTU<\QJ#J=K7:,` MW"V#YM`D3774JPXEU**T#O2!,L'4*%")23(Q[/=BZ9>87M3>" MG@4]=>1>G0N33+Y`L1VETA3CZ&/TSMABP9P0L9+J[D:GSCBYZKR2$]B@.*=0 M-JYV*N36,R=SX@C(W:\V1;B0&T[N MJKQ.]%$40I)F'98I,O=Z_3(,0S,#9`?U)4ZNGP*JX%)CH7':+^0V_ M=Z6QJ(!^2_C]'$=.)ZZN+W-4)*QU-TC-VYH>WN$LPJQQ?,:!T*GG8NRY<\;I M[\0J85=^5TAV-2UJ6=D@5(,K.OXK139"Q`^<9SY>&D MW"/;#_3"#/+QA^;!/3MR`4[-(BOHPC5P->>\Z0ERIK]4Q9'AMTV@"-RJO":Z M@][.E4*8=&WV:0KH#HR="Z+BS,-^N0\%A.@W`Z2:*G;!N,R3[: M_&7'+L@HJH`8PRP*:X&CY7(YUK M5Q\6YGK&A'LSE5MCXAY2P+*C:'1&@_NZ);_H@Y='EFTJAA8[AGH9B%GV973BNQCE(=X103`WY]#X'&8`FZEZH:H&9T2G MLTSB#<%(F\UC]3S[AY$SSX_Z!\>3F0'$MON+X[E9$FE*SBQXF'7DDFHA'3U6 M%Y&@6(-?6J#I#`=[XI<3/KK]_3'.#`I&K$*@(./M:4'9,94U:^D;9N9_6*\=<'@Q=,X=%VU4,\2TCNE.?3;TI("D6 MT$I$D@,@R;:+5J?W$I"RK*45/UDI`6EK3Y><+B]1?_OG5E;F%#307Y.R@%X0OC[`PJ?"-@>L\_HI\B3HUN:=NO,X M.@3OO(W(@R@@9U6B]\J#\/=2JF2MG5%L%W1+J@J'M+7',%;IL8/#NLYB?;[T M`0MJ9AUF)>2)'F<-AEN6J;3KE;6&PFW]`O3Z";'OH[1U!89O(&(S&H!2TBY+C\C.1K]43:_P(,^J, M7'N+">$WT\0)7-QP\T)AZ+0QNJHLQ7!/4(U=4+57!G6G`88P=U\=YAV6>C@] M!X9>YI!ZM_T."BEX%\N]P=UEPX-"[G9@N`7L^)7BSK7EP;`QW%F5UI>PRJ$S MQW]/R5P]<.P(;,HE$"QPU"];+8C&UJ^>OZ*Y)N[-%)+O<[OK/3.*R7 MECPEKQ[&;M#X=Q0\9Z-1C[GAOZ<*,L_6U3G^ZU#!9X<3;,MBN.^8K=Z%QM21 M?&^<>V)ZW"^DYE3`HW/XZ8J*[=1;L1#&F'`_W8N=!^,63;=,_0XX5[^P6395S] M?K^:9LI.0/$IIX(EU9C^4K@?5)IJL?UU2I-MW7]@L;+\Y`7$JAK07UV*]=(" M'S:Q>EEI:SOG'U7LS`SJL/9=Z`PM)T?H#1-WW54^KLM63B_^OI97>M^+7PVP@T4#0#)W#KKQ M.\`*`0$C>*3R/F5H=,Z\B3OU[/7M6M4WK$;L[-8=08J.QI9=BI M#&I])DXL.1-!JWKQ)E:BFTZ]+H#,>I;2`$!+,-\*HJBY`O]]BY!= M;IX[^`V($+O4M/J:HF#$2;N2L1ZJ+!V.\IRZ-*S8-:C5#;3?RS/0)+=FX666 M)1<8SRQPVW6`>&`0-)EC4G7W_W8WZX&=83%7J;%%K`^KST+F-ILW<,:F2Q_K MZ5@W!CL6)_5!O8RTV7<1&(>15G[!8<\CUQO$[LDMSG,?4#-W.`:QVI&*4"$" M!6,U-G_S*"<[/T!0X[PSMD0NS'(?2+.4.HQ_C*$AI"7NOLUYQR4;7N8=M_50 M%3Q'*`=IA\WZ[XHTX]*0SO2+^$D*SWU`S" M-?O^':T1K&"\PH36" M]6(Z)28$NG6`N\,NN7$D)9@IY#\R3W[$=JWWNUNQ@XDR3/>#-MLQFP&;WL2? M<./;(W6V+:-1I`S7_<#-G!1ZL9.AAN&.P0DX7X&]5_@Z@C[J#(J@BS%I&%8W MN2G5'149X_W"2KWA3N^/7AQ8VFO]O5&W+K#0;0GR8P75%UZ#Y`%6F'!EIMEN MUBO#U+\$HI:8_?CV[Y9F-6:9XL6NO$IPLP@]/6>FI^H;5TN2)0@DU:T?OSF) M=TG0\6/2A6.=PP2025!^S;BE]5M=+4HV0F%#?PR/+%7_8N-9)MTIJ(KX)".= M-J0N')>ZJSLR4Y<..NXU7F0C_?PP_@Y]NCB_.AM_1+=W-^>?SQ[NT=7UF<\E MC5Z,V1E@X-B^.9=';_6HQ878F7?D) M:9]BI,^&4O#=LDLJ3&S_0C`O,HBMEMYI=76?[BX*<644N_LY\=[Z%3`=:OWT MUX"'74V+Z"OO"NAMTUMO8E/STF;8S6*_([B/^J/>:!CA'2(88W5);<+/0"4S MQK.M8&R:Q)8[V["V5+W"#")DXMKU!P&62;)(#$;9Q:XG,GG]0D1$=:D48FQ^ M8K;GN)C[6++I7[,P^5C/&-V?B6W_X+`GYQYR&>9`N:^D[^7 M2+@KF[S_&B^9>+?`?$:=4XTZP7];$^:Z;'':ADBF+UV_E>S[1G_[-5XLW_U= M[VOOT,.<@#=ASZ+2R*=KJ$![C17-\2-!$T(Z(FZ M<^0"(>I`\/5,?U_+9>B2\062`!8G0I*V-F_E6VMGI.EJX/4A+_["C1 ME/)%.RHZ+`]"@HHY\VS@08`?5OUA3'[U'"705LI4):UAB[5\6_XNGJ-/Q*)@ M3`C6O!8H2!PC2'/:Z(V"\YO'W'>?'SZ=;W\AQM'VER0CB\&PL]K^\2WP=#R@ MR56,0``QT#?Z`8$^%?,5^`:"^1?@P-*$R)?745<_1N!+1E@75SY6MJ2.E!7& M98$=/%/"':M'4NT*@51\J@K"`XNWY[/H#6A14'66`"!AA("Z(\=;0I>?`Y0/ M0AW>(@>@"@'121J1\!9@T?1W4#RF'+I'M"&M6H3PK&LLU8"`Z7@V(`"&;'/# M6%CL]=LF""_\DECY=1`U;LP36&X:D6=I30AZMX3Z=LBF)=!_FD,NIX;=:DN7 M/%E*!PN5RS<<(V);-T_CC2N`73GP7]/O*II`?,!(O@5ARY0N]!X%6C"+V,IOB9Q!Y8X;&+\GR#K8!@QD M"^Y_@@&L5;U1@::<+=10<@RQQ8]4,%\!>)D52$L5'EBP(!9073#AHO4W/M>4 MP!'9S/$]9RW"<>#1D@-U+*#'5RVQA.1L2LU-J[::0C9B4X$F\O!&AB/IJ)L0 M[6L!.[YXJW6P#1C_3C900&J++*GIJOXRF1=3B%K@PS/YV0(9&07AC]3T-;25 M4^K)"?S3Y\;)U"92(Y*2BD)6$`5DSZL9#$9C\V'!T`R'\`3L0V%Q(,_CH'M?#HB] M=*'B(PRB]&\N/[GGJABZL0)X9&(Q1U.;/8F8403:V5I'>%0%!=7#8,)Z"?WJ M6;/M5.:+JW0:?8#]0_S-L%EKXQ/^#"#MRI(:G'KV5'Y)'F]8AQ5TL;9QE5SX M4X\;S#R>@D^H+/.#[D!(3A0N9]+VY/7T4NM8.@Q@)U;L&5XN.<,PL.LI$%M; MTDK!X+`BB`G1,0/;W0S:A,A="(C_:DM5$I;T(C.NRD!4=@@V#PM/QU$#-84% M_G:RU7MJLNTKY<%D+!.4-2#@)Q,BH+&@KII#MFAD.B`;!(XJNX'FA5*-2IE@ M_C,#,WK9.&JG#>8>79E>#"/R::2GP+G&SW`'H1C9G@#O_[4 M$]MJ\0MK5R^:&'??HG`=,6CV>\\AJ*NI(>RI(4QD42C(;F3(\PULRFQP1)#Z MM*'Y9FL6,8*N.M6;0!Y.^/NO55:H^?\@6+C:`DP$8*0\6-*/7&M7>!'9:'WV[VE&^CRU(%U\%JO`2KEE\#"L=B3M'&D MMS7H\!IDU0VCK+1ZNP=8&I0VS%BF=82G\,Y3PSO)JJ5(G09$-GPB_EU"-WI9 MU0R5(;R&5UB3?OV:6RXZ,>]7I9) M-Q2<#S"*+Q6O7Y=]-A247Y6%#HW!JPNZ38_QSXQ_:<'SI:Q[%OL/L:_!^RH' MTQ>T1?"6OU+9UVY7U8/@BUI6]]5%N0-,;G?X"2TPI-P4VP?.+(NL/%YIXG*X M#817E@KHP[^2U3^IR1]PO^%U&?VHTWEU,T/3%O'`7&R_H"]8S)/;_1%+V$<^ M<_"]AII2[MFXC6-CD)7V_)50_[%,=A\Q^A4:[7!0-"*?J&-$]3-7-AV1VQY8'SF2P,V%YIMGES__"GN\9;I"J16PH("F-MHW'LK/K\N^?FT+62QMMB)^"<_F_K>EC1T15)5@SYTS5;0FZOHA>N=U=O* M*'A=.685GS`'UP5%ZU%%LXDLN@+E81ADXQ@8()MAQZ]\^O[V$Y-EGNA,7EJ` M/F#GRS&Z;H_;?KD4].@FJ%Y$5JT'XJK>&23+@G:VNE M::77]^P8LO@]&[*2^6?,I?.];.%./[6V%*VQH3LBB_3":DH/JU$U3VS_0/%I M38:*4[0-E:I"*W@F5*'5,BCN5F6)3-6TJZ)$V]YL'ZV=4[61#[9L@MYH76'I M5RNKZD-5@[:.ABH.RKED[E\*=*P,S:]9G')"?".SR%2Q@>X;WJIDF?$O"YBG MH+-?T1:4L/G%2Y2#F&^ZVEO@L@HF%V^YM"D1Q[+JSGT"AJO6E'DG`C!H$ M+56VNKZEZ#A`$,,9-E+_0@\ESD:[`0ZE5C$'W1S+"BRI5S_,R\`&4ZPLJ`2? MW.A:S-F3*N?T_43:A"Q/E&^=J.HH&;C$U/^(4Z`E7S>J6-`%7U%UGXY0E:<2 MT6W@8!RI4MNI)]4K2UG7CK?DU-P8$\R3L3RK\8R]*L'_;^]:FMI&@O`Y_T(W MH&J-7P(,Y5!E(&39A4!"..2T)>0!3T6664GF<=G?OM,S>DNV)=N2QG*G-EN. M+78?J$<10AH?C)D71A^F9GS8E./W604`RX,[%+X6NJ'1L1CHX7%/>@&*)._NE0/_ M\0GSM&?7JWALI&//-?X`,TBT#D"XQ]J0FTD2]\?:*S)*IPZDBZ/DC)S4(2;S ML@*J]RU;"K&%72L288_2(VQ(RLBUB@`][/#[11X[@#(2]`#*,U.T:4#R?>AK MOQ3%]MD"%.U5HP:X,`LW5L/6#.+>Z0#L+0S&'$H/%Y+$_,JG*LJ$PXBC6'O*KQASP]9L%Z]IKX;6G--X"-]$^&;Y6]&MW-L<1\=%(M\* MV.3H?,^+V\QMO+W]P]INSJ'U2F"]6XG5/-,,<<$LN#;#1FVQ`"C7(>1"QJ5; MO2@YE^%+=#:8YS!\V?`LZ7$P&N@F&.B\^4,1$7A!:ZUSNNQ]"[*>'.QW#L+] MKOSP%F5\'<;W;$++KW`:@R!,/XK(7;@/R."^*UE[9>;\'TZ'T;#*-JS*XF1A MX^/\T/G5@I`Y8U_+5G8AHA)[CY^^P>XGY#OP0VOQ$P@YIT.KS1XDFC'DN8R$ M4UJ)M:F-1>ZV]F2,SF6$8B]7N[>I[T#B4(5#8!+1>1?"\QZ?[^*^6[$+/*FW MWB`9%]FEWZ1\;C.&)^4!LK\6M?I+ M-^,%S],+A*:FB>E9X1*PN>-A ML]MJ(JBVEG[4;B^S/&[O=WQ'XK<;9N4C$4_P0YH<64S$0WPU*UZKT`.#Q=?W M*7!Z*'=PT2M^5%2"(-14!N*"VHUF_6;+N_)%@.M@5T/@0(`K5V*-7[X4N]?D ME1A*>T\I8S,OZ=1S[%T&CUXI>E7KS!CV)`Q[]S3@`[F%>W/E>_SM(]R]Y#M' M5^;+M,*@T\&@@T$'@TY!3A8*->5[^(,YD2;,=)6Y<::`/9W%6Y,EWT`!FFM^ MYP!/;&MS5:ATTROZEM`Q&F=MC'/&Z#S?.CMHG6B=:)UK1BRB<:)Q2FN<"_%2 M>4%0$035_90M0OZ=LF7!E]=J?,$^H:"RO"0P7LPQN"J0$2:*1"&33;1A)HM=ZZ"3S-5(DB5YKX)9H M&P=)HNMEGT@2O9DS9B2)SA%,D21:VM`H@^A($KU!4TLDB99[`T&RJ0"21&^M MR2-)M$0C`Y)$;\A>@^Q\NT@272>319+H6$0.X$\A`$S&,]#(P>G`HW6[G%CW MFD'N_;S8$O#\0&[/UAE1M:+P;:[Q(U894;16[Q":05R%5&UK[]EC[*E1M`?8F`XQF M1KZ"6,ZB@3F\IMHC-?C+,S,885*#F)T@MUC-)]92B(XV4Y[PR"U6U')%#@:G MY:P'N<7JO!$AAV46[O7(+89^5.Q@CWP7\^T?N<4"$9!;#&E^D.9'AI8J,>PA MMU@HZ""W&`8=##I%.1ERBR&WF/K4+$2EVU9J3ZK=;W:7K_:&]W7B93',KW&OWTBL.E[IBO4EU MCSN=96ME)I!7254]FM&ZK+#E:DFHI/:.9J@4KV-@,!<'5J3[D6:1,Z`M.Y^, M7XAI54A5PSQF#`."014A8!J MFH"=E06\((_.E6D[UA3`0Y>:3@:"KFZ!'_US/3&?F3..H8"?'R^D\=?=S<1Z MULSS$:OW3#-_?QOPC]\F#DGT/,@=$7V6'&4(RWX=3LPS2S/U4:JTG>.NFEW: M)VK,P?3R2\P/_BVYKQHUK]DW`UV?CJ<&=)YA&BP^V(Y`<\U7+>%3PJ76*D+) M2J4$BH."E%J,P.:E>BD[KOG]II8 M=I;6:B\86I+#9S3^Y*ZO2'&3S7-:@*R);KSB-V)_:N]NN+V%(&,^DRLS*/-/ M<346BKZUH/"\[=[HI#?\>J2I3-.,7;9&+PC!)6^M#CGL_[1N'P-(ZC]Y7="L^.(U\T49(WB7K[^28FE M6?KH@Q\$,E'%223_5W*DE$W">?Y?^H*XF7_^U*<< M&??$!%!L?<2,Z_/.R'%>3IK-M[>W?9OH^\^3U^;YU=^L8O;GJ'5X>-SK-X/7 M1)G-4*%]<0?7K+\2JZ7<>;7,5%'[Q3>^<4U@SS=!#E]9NIU9RRQG;E*"5\ M++6SN(F=$%="PE[(O;"3JA_\-4:Z$J);$@^G*B9IWRQ:QB2L MTD9V1('SA*HZHK.1'5'@*JZJCNA*UQ'5;`=$Y>^NL%2N7'YU>?FOV!JYUSJL M6@/6`SUF1%DU@+U"+C[?*^3/CL4H?$KMB=II'YVP7_I-[TM>`+P4?9N?SMNQ M`FS^Y<)W'^SA';%X"6X!0_K*='=U@^>^3`L` M`00E#@``!#D!``#M76US(C<2_KRIRG_@G`^^5"W&+^O'F-/RQX_G%^63PQ__^>TWG_Y6+IYC`25.!^(9,7A?JKI31)1`C8XGO@!6:A)"ITC(%OA[^<$Y>B]_ MF\P9'HY$Z>^U[TNGQ\E_W8ZOU3_4[\Y[__KI]L/#_^^NST_[?_O MJ/3\_'P$[A"QH+4CAXY+Y;)2RLX(QJB,"1<*U:(@QY<\ M^+Y%G0!7BB9+1@GUJ;P2*ZNORB>GY;.3HQEW0XH.L!=IQA=H-`97V:*B;'?\ MP]EQ2%Q5F-$26T66MCBYN+BH!+^&I65UKG@1#]=^7EG\N"&-8]1YL:_D]-V" M5$8]Z,*@I/X^=IN)V"M*L()=]NMCOWIWWZ@W:]56I]NN/];ZO>9#K=9^Z+5; MS7JUWZA?5UO5AUJC=]=H]`]*`;1+,9_`U0''XXD'J^]&#`97![X8N^55,XJ5 M[W9HI;)&YB#/\;W`<5KRK0>>64O<9>]ZJ70\]@7=UF*EH)1]8-YC(L:F%I^!NJGG+*.<& M2(G%PG!"KE-E462(.:L6Y'\#OSDT]K>E1(7[XW%06UGJ,%Z5'S`ZSFCSE2HT M`["2SZ6.=*+:1[(*REQ@RTGH&=3LL/A@'Y]5Q_''B@=PJV/*!/XC,&)VADT5 M[2'G1IOIO>`T[`7E'-U@H;V!VN6/.:F6,%AJ!\0\O"EJPK"_K!'L,!;8!25= METGA[#GZN@SN)\#$O.,A(JK$;?SNX\D8B)!@#$X66\1>MN*1ZEDZLX2E!:J: MSYC4-W9@6LG8R\,&%KWA/]AB>,>A/A&\"P[@*9)=77I+`@]Q1>R@90-`A)U8 MP':';S7$1[)CJS^JI8^YXE/O,U'L2"A6"H#C0=D]2 M;3$"EB9$T`A:3XT.G)Z.7N2 MV>RZ^&83J=V1C=2:^>"F]BRS?&%8,N&U.W1YH`+2]2*=9#'(T6*T.Z@)`4L> MB_-2L@X#D-9T^V@6TN:!$B?6D1*+6>15.G=*AFWWV*S7?[7_)Q=CF]N$FY\S M\9JEWD(2G\EP=D\&+4J&?6#C\(!I&GYTHI;SIX>WPT1@([;4D8T*-3LKN43QTBAWL1:@D M-P8C(!Q/H4D<.H86Y?P:!I2!G,M.S&NRC/7DS6\Z1G>PC]U=LNJZ>*%:!V$9 MA-30!`OD25QC2@*;F!A.+E@02E-8P.Y.&U(U]M1G4ZP8_&RCLWOYW6'+4#^1 M$)UD,3C18K0[9.R"0)B`VT",8#(,YVO)M1EVL&G+(47!8I"6Q@)9#AL^538! MM^3GKY/AW.O+?^\;#_WVC?RE?=]XO33G[:9LR77>UBRG/#V5[MIA=&#L0V&) MO-8>R`/>A2D0'\Q'[9M2>?=LC6DC"XQ-4'8'FS7*17N@-KUX3XY6QC@E*F4Y M!UN@+$_X7:]2;B3,&B4"$U_.!^T)L,4MIL7J92$GUS#`[S&A3,XJ32*``1?! M=F6XEL6DH$Q@>+K:9!7EL(""AFNM32E*6@D\_;X'%PDD@6A,Y[= M(UNP&?!`"8VJWIA-@'!3_)]0Z*U[08))[5Z3+^:+F'X?$LB;Z&U=H^EB7]$- M[.[E+Q"73G@-!,Q!KTFZ"'1K,.X2UN0!+V;JC5S-"4=U=KO="Z(E)8FAQ(M< M0;C0`+0\B-;L^\OU5WL@^XUY]]58(L^@Q7""<2-'=#PDB_-@9]YGB'#D!,Y# MW.#3TI7Z_$B&'6"8NCMVIB]NKF`.\GIFM_N, MJ0LYJP59"R<"%83&N(+"-^GF=1\O_UQD,O.-8>)&=R)9KM0&?>F`%SL#1*\O6*Q!J* M378F6]D=Y'?0/-@5;P_J6)F"N,:S!(UDL6G48D^18+;;GN!V##;`WDJ'8$$( M:G>F,9-S!!G*P2/L3QN<9"E93(XRV29%0EF>^[ARYG_QM!0WEXSBQ60RV0IZ M^GZPA3X#[,61XA<$\[H*[CEBZ"OZ?^K*K7\;0D>U\RI:] M@?69H>Q$77"HC`J"I]VMCQ_[],L<\R]MHMA^\==:V^[-"?U#^!;;9A(N`\2A M#HN_IM2(+%7D!+,Q&(`CUSNK=4X7"6@3O>8&F)FJR+L#[$)KN`MDLU=1TA>^ MT"A95FD[]/H],HDV,"S(TS9>R209Y@9;[EQNHFV2C2?2F3-G$\KES?%KQ%,; M6;A)EK,[X-0"V'C,71;V-XN^20?8LI_=H>':1C>4I7B1B%E^W]F.L93=9U2K MX[9L-R.22NT[W8E6LWM:K\.$@8/CNG)$9/_I#-O#[NO8SZA/'B`57L0>R`87V;?>4ZPF)[NC[:<&IF7@^M7UV1>2X>*[CO[ MZ>RG=X(+>YT@N/ZR1I!^0;U5\.TYP+;M#!LJQ_;ROWK53I:]E'"9M\=ZQ&(& MPJU)$-E6O\-@@K"[6C\NEXU5XH9>')/:$U)5]O9<))V-#;YCR#-YO>M)ZQQK5\L'==/0/0X[M>2]JQM:]S'6E'Y8KWVK<\U%1O/N;2 ME,%SSH)KLNHR)IO&S#S))?,>7'0D:%]E%X?>]G.8)80N>KY'`AA&7B)E$=G" MD!1%:/?1R(O2/U/V6`L``00E#@``!#D!``#M7.]OVC@8_KQ)^Q]R MW0?NI(7P8SVMU7I3"G1EHH`*^W%W.DTF,6`ML9GMT/+?GYT2&DH2PG!"F/:% M!F._[_,^C^W7=JR^?7?O.MH<4H8(OBA5RY62!K%%;(0G%R7$B/[FS>F97BV] M^^O%\[>_Z;K6I\3V+&AKHX76:KXW;YF'.-08&?,[0.$KS;3G`,L*#>+./`ZI MUL:8S`$7'M@K\<4JOQ*_S1843:9<^[WQAU:K5-[HM4KU5/NWW_]B_M.\.AU^ M^/3^=??OZ_>GM>%_9>WN[JX,[0F@OK>R15Q-UR4D!^%OY_)C!!C41#"879Q, M.9^=&X9L=#^B3IG0B2%\U(V@XLF+Y\^>^97/[QE::W!7#ZI7C2\WG8$UA2[0 M$69<1O70D*%SYI=WB.7'E<*E%EM#?M.#:KHLTJLUO5XMWS,[!'2,G#4W'@=3 M%]J2"T-R5_FS7@E5EP9W9&*CR9*+ZMG9F>'_&JXMS-E\53UL_=1X^/%);90` M9\6OT/39@ZB`6I0X\!:.M>7CQ]OVIC^$N6$CUUC6,8#CG&@^V'.^F,&+$X;< MF0.#LBF%XU@<`7`IPJFD_Z6T9NR-:2J`4,L;05V40BS'FD*,4=;WQ[RRI=MP M##R'*T2\:5LI7N("I)+@#=,*T/J&=!>Z(TA50EVS&\(9@'R*,&XF,7R8R*9? MF\3R1/P\^&MBNX4YXHLV'A/J^O/?]@@\[MIZ8-R'FMIV*`K171!&LK0COJXY MA?<<8AO:@5N)7W642OC\.#2O;UK-=L/L]&][S8^-X:#=;31ZW4&OTVZ:PU;S MTNR8W49K<-UJ#7^4V1V]Y,+QCV/*B^V^6,%@/H4<62!%&E%!_;K+`NH0"S!+ M409#\7G3Z@Y[5^*7WDTK.S$V715$A$1@N9*?T[#8XK>HLAQD@(CG9JL[6(/3 M,`?75YW>Y^P42O1:$'W28MQC1828Y1#F47@)&&*]<9]")KK`?DNA1*/YK('2 M0E!!71?>F99%/+'(PI,^)5@\6E`NO9A8>S6F`$\@:^-P'80M)-AD^U.\C_.< MI5`$585D;3P7;@E%*B0(&\N9TAC7*B@:<&)]$Z,'VO+T2^P:%!&8T+1/'&0M_$\E2Y5<4![/LO*'8E*\_I2OY6S/ M@;UQ4+AH>%3NPX'2\"[0,DO3C_U@];/)&/0'

!$7)\1,LF=@_?2I1B2$_\K;XJQ3+$ M5H0%@_)(CV]TQ,M M5E)_2Y(LB#5>M.,5Y6LU'UD>;H9EH8N((,_AM)F,QLCY^J%_(P@`6&RU&;P$ M^%O7]!]E7KCQKV\]425EHPRU"=\M2Z?+>O>2RJ0-7>'(2<&_P&T3?$D!MJ;I M!8AI=6P*Q`4?+4'M<)/7*G6*51ELB\>XW!]1\4"0I0QMS#CU+Q5>`0N:KCPY MBP$>6_V@?2J>]_!<&Q]JNK&L-BS@./L$\W25ML1<*9\^Y@>QCH?V14D$#+#:3V5L0#NXRVL%F<)2D3+4MP/\&9W:^M>4JH*W8O M%R'ZKZC_^M!:).S4T[0\BHU[*@J.;A\?-:I6,27N'].T//0.?X=N&REU$BF% MV_UG*F41S@6R4S/G,X/L]&:K_!:YR=VIZ4%W)3MTYFU:;W)2W*%[N5@]7B-( M!6'310?.H9,NPR8U/K8DFTA$_.G%,0W6S1!WGJ;C;10H]Z;HTUL'<3Q7Q1W- M>6E=L.2.9QYK-139>@(UH4+B]O[=N1:D=Q4=RA'$);VUFYVD^K M7*VPKQ.BT-9W5J[^TRI73U:N_NM%T`Z06]\]Q!_SWN.A90SR^/I'\"HH(=A? M[X)V>A>T+)`L``00E#@`` M!#D!``#M7>MSX[:U_]S.]'_`33-=[XSEQVZVS;,=^;6KQ&OYVMJDN9E.AB8A M"3<4J)"4UV[G_N\7#U*B2.)!`B213K\D7ALXY^#@!Q`X+WS]MZ=5"!YAG*`( M?_/B].CD!8#8CP*$%]^\0$DT^OSS-U^,3E_\[:]_^/W7_S4:@=LX"C8^#,## M,[B\>#N^2S8HA2")YNE'+X:'8!P\>I@V.(]6ZTT*8S#!.'KT4L(A.23_\(\. MR=_6SS%:+%-PT MT]-#'!Y%\>*8\'A]G#?\Y`^__]WO6.,OGQ*TU^'CZ[SYZ?'?WU_?^TNX\D8( M)RD=%>^8H"\3]OOKR&?CTF`)A"WHOT9YLQ']U>CTU>CUZ=%3$A0$G:-PC\TF M]98K&%!='%/=G?SY]4FA.2784!.5+IDN3K_XXHMC]M=B:T(N2+?-B]3?'/,_ MEEHCB3A;_9(Y_=W7<13".S@'C.>7Z?,:?O-)@E;K$'Z2_6X9PWD]N3".CVG_ M8PP77@H#JM`OJ$)/_TP5^L?LU]?>`PP_`;3EA[N)4+(O]FCQ3L=]R7@+8Q0% ME[B=L*7>/4M]GWIQ:B!WH7]ODL_(-@A;R5SHV9^T4>J%[:3=]>32\DV4_N*: M_+0G-'Q*(0Y@D(M-Z4C6,6/#=@I*.*<<^46:+T*Z:T;QBZ(F7A3WD;F7/#": MFV2T\+PUW=\^.X9AFN2_H5^+ST8GI]DV^AX7!T6[[PTKADFTB7U88D#^]W,+\9BB7R@4 M33F\H%\]PHQ^L"$>?;A_\=1RMFB$J%R1J MKM/C85;8#?PX]OUH@U-R1"2'04Q^].$*XC2YC4+D/_/_JI9;8S+&:Z^MX"8+ MD?`$.Z9@G^LAX!Q=PVU;195!;#;%_2&:WVC2'[PX]G#Z?($2/XR230Q5&-;H M:(Q:?>%,<)J3!W1YM%I%&"24*]@R!1X.0,S9NH;1 M%@HJ@[7UA/:'V@GV8TADNX#\_Q-\&\.UAX(+.(3;"#S&S.8)O]--S+UF2#^@C"F!P]OR![$@3/%W#V*,GNK&?HD=V)QD_ M)&GL^:GPJ-^8D(7#?EOAC3Y:X_MWX.IZ^L,]N+J;O@?3V\N[\6QR\Q:,SV>3 M[R>SR>7]EZYAO+VJJ@=^LXGN]2L6K>#,>\I6W!G$<(Y$`!:UMO$=DHEA]J$A MDT"=.F`>Q0`Q1B#UGMPSDRB44+.)JB>C/R1MPM&7C%HB^'1YU?_D7"/XF=R4!%^Z@M-+'S?JPQ- M0)S34S@[^A)3#5W7L%HWTNH!0P2!OG=>*ORA`F;M9Y^ M%6,3`'"Z8$<84,JN`$(U\AP2>CKO;W>X\E#,C,`3O-ZDR35\A.&K]W#U`&/! M5B'K8;QO:(AC@B%*'C#Z-'B0%ORP'\1,G_PUD`:FE%B,4&U/UM4>)#4$M`7((JM#L&7F+"XU5"-$I?;D#;)5%J2[BN&O M&XC]9[U]4MC3YB:I$L\$D`7:8$O<_1U2I1+)]J@W97W&DG@ID^8:83@A/XI@ M5]/00F2(B+D)J+94P4^4+F"$G8.3>.S5V`ZYYOLT@Z603&MZZZ%`:`8K-+%@ M!JLR-'*S>LD2L(""@(7%@'0)P9K%QF3>+L[/-;#4Z:%J?1)IOC^`4/V.<4#_ M=_GK!CUZ(8O99`HNQS`(`-2(A#'`V@AL%M:;4@<3HP<.@HSR2_([X%-LTO`6 M]@/<26/38-O5>*4&7=N#'F(%ME%<>86VA[;."MZDJV"4I_.Q53E'X<^WWC/] M=$SG,^K!OXKBRR=_228'3N1O*$V6)ULST#NX)D+1)<0^XZL( MP]2+GX&WHID#=*3-5'%8/!0@'""?JAFD:)6?$8YHP7M'5^8)_*=<:/)M-'V]@5;\O,YJ&AFR$JCPS&XW0[)E)T2F@+WAXC MUVB(\4V$H_U`HRRL3K`F%9W,X]FTA#(*;6-AYUE`Y$$6D?[2-0#JZ:$2,]9@ M=OH.MMW:/Q11#:+6EH)MA6*8Q>4P-&UINX8FQ=#K0VP54]`??O+L"'+,N4;> M`PK9MDE@[DLC$I7=C!&E*Y@)M'(>3H=PZRJB#+1F4]1C^!5/6T[("9LFX2LB M7^L;FX=C284P"LO**(,U)^T:G.0CKP1J:>A_H%AIK0"^.LA3'/%3D5GCN:$[%4]:RR\T2E75BOL$##6 M8,<;4.;@@+)WSAK47H'"PF(MIW^`9*T[[^-[LKO&R`O%=43JVMI+WZH3P02: MA!Y8Y01=`YMTU,)D*;'F^S04/:3ZU;M$K2V8A:1B&#F.HA0F(+OIVB[D:$%N M:?'&/>%=0[UB\%7+E09X^D-^OEM/,1%J'26(>GZG75TP!Z/=?C6T8AT5]" M`[O2YPGVPPVMA'\;Q53"<9K&Z&&3TOUK%E$S=813HJB0>=IXW*;"Y&>9B9VJ M?M8';1;WO9/H3QX!QUV(WN:FL"=H28;BV"[WHY`!*YZU]J/6WM^_)X#Q\3BNP M7D<#&"/`.0'."E!>KJ"JH5** M@;.-)ZO'H#PJ%_HG"Y8^CW`2A2A@_QCCX);'27O\L'R%,!$9>>$V3B?1MWU8 M9V,>^-?1P$T6PYF7H(1%H!<$<`7_72NN$EO8*60&#TO/A&X?EEY'H*NP=(FP MUL/2#S8)BSY[">8YUWX#U`T'VSQ`O?V('0I5EVA-,U1=">C^UFPA.%`>BU?3 MT'@-BIF;K+7]RH[ACH?-%64F>H/*E)KR#[$^Q#HHKP,5>/H.(A1Y\"T9Z.U9 MXF?3V?@:J(O]=2^A'+*:8@X7NRCTVELPC#>-+^+A33RM^8K\K@Q'>5LKD4=" M$:R$(64A:9P\8/1=0866$NI"E!03,?@IFX8+)#8>CY`1ZNK4K2&\4:ADZ?&( MR_T<0K5GN@AGT#*4Q#NH`_1(_7#"-"LU;6#YXW$`EK)(XFW M9+M]MJCE,/1<[PU',U`>G[9&U(\/J:#7WXJZ]&),EC@MHG*_]&)X@<(-F2G! M(A*U-EXW"C&,O(09:5J"`OC9VW:4!S@(.!?G@DX5VBCC2VM6!C$9C'%0=:*K M#0CUW6R:$Z2"F5_(KB?CL\DU.S>`\+C MHR/PZ=')*5A[,7BD#+X"WB9=1C%+&AB!-R>')RX`)A>E2BGF7>[S=(;E3^5&@%KV2C](-H7T` M4F[+(PQY]-T$SZ-XQ7WM]<8R[6Y&(4A-!+-BH:6?R2R\LL#*&1M84YT40Y": MSU:_:5033&3@)F7/AV-6BU'PM10VMY)()1/$"&2$-M@1/P24/.#T70&8KA[J MDI/4,S)`*J=^@)JTB[W$SHX"QPKO](%_O;)Z[K(ENO2XI?G.X*#9J0U"U_3! MU*.+/_C?39*R]1G%9'G&:19;)_+Z"]N;!P*H1#'R$13HN88EY<`K?GB]2>B[ MM")-I;LB(SN/R%$";\B!-"LS&N'DC&;ZP^VCV3!YCS!9V/3`D64&X6"?"K($4`BG;WSCU#-N_8_[9^$U682;OI[#91]IPLC]@+ M)SB`3]]!<3'`7 M^\UZ'>I4U%9V,]ZY=`4S\FE3'LGQO;^$P29T[V.NJX/RAM1L=GJT`F[ORM/Y M>;2B%>39@>`.AC2*ZCQ*TH0%>IQY"0RRMT@29=$E0ZKF-D4[PS*N<#%B]$%1 M!-<0;4E5%>ND30@,&?59L)*)+\>2/AW$>=:(9,V.:==_;"Z[7E2GTZ9,#16H MPSB%D.IO;?P`T6)))F'\2&Z-"WBSH8$MTSE;QLRQ-;Q)(H[= MA)U4$ZIHXV%AQ"P'VQHUNP.."$K"]N9P4HEB!"E*W,$/J7+0%?3H3<``%:TF M>$WVQFOX",/3VF)#.CWL5;`2BV.K,T?5KH[]NRBDQ\Q=Q=G=.,8Q M2LB?+MASP3QG^@;RYW0%:Z`S=G;>S>Q0$28KJ_#&PH*]L4!7V$M:WACMO(,` MP\(+S^2'3U\=@H-/3UX>@D]/6"3HP:>OG#NS=JWVV@<^.P?@(%E#_&8XWJ;6 M"):@K(?-7"*1.!;2BAC]0Y`9!'8L7`.WAC8DV3_RV>G8H.MG^\AV",5',LGFA:S&-3DI>*T6V M94(H\J1Y'/E?P):O*V@U4I=.36S-*;94'?O,P[_HQ^RB,`5.%.E7;F\4TBUF89:*F' MW'O^33C62N"27,\]/MR3A81-Y]M$G^SPN!];)<"+=G?SQW8:"FKD;LYX45/* MEMMA?E]P#71--5-Y)*?5'/8'T=LH1/ZS[@XF:FT,0(48)GACI!WT#2J&7`:2 MENJ'>->OD$BAVM`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` MA641)>H?`#E7"*-D"8.W410DS&YU!Q,8/TJR[-4][6%*+9[1AI51!XO(00MH M`R4(P:8[24/$#VPW5/[@XA@'A7)169A5,,5W-*0^SI*7DX9!!C9X6(Q$L#AD M6^$*Q8\VEXKE?Q3DRD/^`II$LA4-,-E<6S.=J%H<_V`=7CVF4<_GT"?[P>63 MOR38@'?D-#W%];7W!_-41JBK-T\UA#=R)I3>/+V:W(QOSG^;;YYJ MJ$KSS5/MB1XL3L5Z[*JSGAQ[JT1F6#%=Z@!@0YJ MV:F$-?KN9"[JX1[L[,SGU^FFM*74-.;U[[=$"2\QV-6YK.Z2*[ M"J./JD.3M(L%IZ1:(*/[;TZ?GN[9@VJ,A6O8TU%#U;6G.S$#UAU0QYYUD]C; M1"#KI0<KZ[@)[R`<^0CT7:FT=$8=/K"F156 MXEP`S-BXAC5]-901UW22!GGT(DN$TG_FHMS!YL,6`F&,MK:L!(;+9S:U!B3O M5$CGH\>(PZP2-PW,I5<>'(CN^G4MS6,,Q>R-@@LY67KL"G*Z-J_G;<76JV[= M5/I!`B+%&JA$0JJ`T^>'>[T5AN:^)T0VZB41?JX%S2U\I.6"F'V:USL`84H< MK#EUFTO`:`1ZZZ#=0(8Y;,B543UBZ`"KQXR[W%)P^41?;E#Z,L3MS?/>5**8 M+(TM<0`Y=>?.%,KA5S+*]*:BQ^QF6DCT-H[FPEM0L85YWG*5G0E"&#EJ`B?T MK&8HMQ-3:K'7E760?.3J>"O)QR(8#)MOHS8:J7IUDGECV70D2K]QV'JDJ16= M1!P';$CC($`TF]<+;ST43'!FHR^8NP3HT^AHX?%H7>&,D@RV7,BY#@4C1"-= M&"/7H*>OC^KCTLUF:ZB]CT67:>UWO*7E/6Z/O9U]C>53@1'X].CDE.`K!H^4 MQU?`VQ:O)7]\,[$>`6*8>P5DQ9=LU5$I4*-\$:Z:PQUP5 MA%$*K]$C=:P3S2X0N?AD<8T[2VO=P^TE6+8@9)[9TEIXHVL+R\!"6X:Y4WL$ MO$*>EE?@:O/HVM&8]6P`=H<^2`I0:_55,H,,`=]S!1\N66;G%AD2J@WM5,ZI M96Z^!OW,+<%1Z!K4Q".OK4,CT?L@02%9A"0Y*D4).S3I!X>(N]H,$E$*:"U8 M9,L)Y*QX:M.2CK_A4->9@B`>V=>N"RGI8?!B[D_J@S'?A&GPTQBQ^O=J9 M(J&[*F_)++J#=-PHA#M\J"PLV)_L#-J\MX^VDLGFG M&FJP&G5H-$<\C!G.OM:J!KNN%L60.0+D?AAO8#%K5+`G:'7M("]`+*!A&1M* M-??V]O#>O=DXI-6'RX-Q;74V488Z>4$%NT&^Q#=$"V3I3\CMQ7QW4)P+.V=K M\XO=J6+,?$Q;&4$:@3B7C!4JSJI8D=_CNN2W0A+15C;G`D;ZF@3)=[('>/;I M%J,!"51DH3=LV\""$ZS,S#1GE4/::JQK*QF5J:9J08=QJ94'6_6DU4]_CQ93 M+X3)'7R$>$/7F,@X6FIE;@>M9VMD\J0D#^GFZQH.!(.M&#)E2AXP\4U:,UC4 MVGZZF[UJP;69;FZ6"E9H09G?9J-(L.Z3J+/8HX$-]\^KAR@LS6SU[T8/G=:R M,K+/<(*`4W0%!<*A%E\IE:AU.$?'^`F)CCRU3:T[.8H"V'9Q@)\H]7^X@A(= M%:C\'-5)&*#>+'KG-29CKS)M0\%-\%AXN[;XJ*MK6&RK&F']VE:3 MVG_FXRP:^[]N4`S+,36B^Y^RG[6L2*5H1DCV4`-EV7S\3JQ-I4Z4RY232CW^EQ&R?DB#^,4 MM[?Q_(5<%)O^0=>PIAQ\S8L5.A/1E3WA$J>(P'CS$"+_*HR\,E[JVQC9%80L M37#!B0).%3"RKD!#.N:BD4&A9QT(;-)50*?YS+W9>3_PAV?O4BU/1$>,_*JM3 MV246GLG^H[!]A041H4$ZY?DX=1Y,;Q5M>+1^,15IL]/2@@B4\#>R8/*2%G)' MA2?0Z;/(^=!&Y/@[2JC6DYW6T6I-XP[PHMCM"-S!-=$8#VA80A"@^1S2!X,A M>(#I1P@Q^_6<&IU8QB,[3?M1PB1M(L"1*Y^\3E"0?RH[_.KT&'6>97?.O*>L M#,@5T1QS*DW7%,+)Y1.,?90(G8)-*)A'I3<7U\A3Y#V1M8'A')%%FZ8Q>MBD M;*]+(W+RYXSHXN`9PQ&7P!7P&^BL$N7>=HY[]6277]@K/ZE>]68+>]CP:*O$ M,0\QKWM9T::1Q](@-$+'FXYD(/>\2ALU+GH]B`U8L$NP.JKM[!?HLK<2HG)Y M+IO+P$AN#?`W$MZ)TF(BO"M`TV>YQ@22`=+7@"[H,Y@1,XIF4@D0+^]CH7"C MAD@F*R%G`/[DK=9?@6#'Q#4\::FB6OE0>WH&J:LLBH"QF?UB.Q/XY*0! MIPTH<<"HNX(@#044O3U:$]"MV^_[*-P0K-+'@$,8UZ&DOIT%]Y^`M047X)8R MX*1=@H=T[%57H%3O/::O;!X2^.N&GOH>612$ZI%E87OSE!:5*$;)+5OB@%-W M!3K:HZ]DN^C-Q,!Y[M0IHZCKK^[7389[G6B&X2N,9%X6OY?T]K:#4.6V[XW$ MM;6BK0FMQ'8QU`9]1Y(>J>^@#]$C%4R_0D2E8Q?O1@J$LQ']16X1D`B5,D]I MQ"X6\8Y3MPNJU;CTXBS-A^?&2A.I2.,!3"DP>SSRT,2^,R)20%T)$">RLK:" MQN:'':D01B<=ZD$$0)$>`JBB^BS4,Z MWX3Y%T4`*&D7&R4,E`*9@&M+GX6(']`"'H^07,>B^4O`(VMH8(V7GQ]V.YMK MJ--15$VQ`I:V_;;1ZL?T%N]Q)?VWX[*YZV6M96_&R<,B"D`:7M"FJ4@Z_SL4D4W^.W M+V3$85!_/Y4?PS4[FW\/&PEI]&7,.?'B4)DUHL@,7+IIC6BFH\J'LL5,]FJM M\"$,$AIG3NM:>40;T[GZC3MU/QMV"SW1#(T7C`F@4\X>%:-L:*Z!SPN:Y8^4 M.9ITH*VD&L-%DPGL/U.&AW'O,B'.>'Z(`(^J7M8R8A1B&7V*\X?Q\JJWWI/] M@M@6QR'U%]8.QK75HZD,49J.%MAZ?M.K)A6"YL/EZ1#\9%1VQ*@>$S":'*.>C@:VI3Y+9:0,:_:T5]H!4%@DC-]S6M33&LX2] M446O[)7(-7V)DYSRR7D?4TZN1C=)U%!&FG(:^K3'[F.8?!4NG_QP0TOK*MQ` M6ETMV&;U!>P@%T+I#!AZ/-(DH;:#&L;FK*^8JN6Y*11[-=_4UZ43/SL@[6+# M:*,4R-!>4U.!T$G,Z:BBQBJC.3E=^3C&A%O`\E1";U'CV]C_NY%/HY:5D8DY M)P@H15?P(!QJT7,A46N/'@MAE9VRI6.*SY=$\^3&MRN]\RX*V9;H(3R-)<_S MV.9B[@/I9MCV38'DH%HH7K7DC,$!K6+%0^U<@7S'FJVX6+I$U``/K<\DF3&E M1O8>3]]C:A9LG#^3_A.CZ=R;#O5#%CZ!7J/H'J_?\&,6:4,@2DX'F/SH\^<) MR/&`@SG9IJRP-F3+0.L0*M/VK)`VO^!;'*`):HD<8,<$[$O"3IN9++0JWU[# M7!S78&Y3LQ4C@W7L])I7Q;\)U$R"1.7VRJUL9$S5L36R8K'W,`DQ$&SHLQVL MKB2O))J]HN"NZTV@CIJ4(?$T].DQ6,?01[*LH+TF%NSX589F!\H=/=>@4#?6 MJOU6`O#-T'VA_UR MOID?MES+EWJBO.V#N*ZM@`Y5J^NUM0:MX=3D.T> MNV>1FZ^_)I0[C7AH.#R3]96Q`G[&"Z0[9K_19=5"@TV"'UHAI,\*ODDZG5// M17)/EKI@"91;6:C46\O6Z/R;U4Q?4*(@(51=0Z!@T-7ZM1)E]^E-RLR.A<=N MQYMT&<7TNR#T)TD[6?`HZ0AEYE/*K:W[KQ?ON+@&*SV=5)U+^C,U%.ANO7@: M,]-;P%)\R"&#":H%/F%GRR!4"6D5C(19]C8I8<.AZ38<5=J1PU)O#OM]A'D& MXU4QK$8`QMJF5AYA%@E@9/!T.=Y)-NBZ9Y?KU5X`L``00E#@``!#D!``#M76MSV[C5_KR= MZ7]0TP]N9]9QG&S:)+-Y.XHNB5O;TDC*II=Y)T.3D(2&`K0`*5O[ZPOP(I,4 M`8(B)0*,O_@BX7:>Y^#@'%Q__MO#RNUL`*$0H_=GE\]?G'4`LK$#T>+]&:3X M_,V;UV_/+\_^]G^__]W/?S@_[XP)=GP;.)V[;6?0_]B=4!]ZH$/QW+NW"/BQ MTW4V%N()>GBU]CU`.E<(X8WEL1KHC^P?^_F/[+OUEL#%TNO\J??GSLL7+]Z< MOWQQ^;KSG_'XG]U_]X>O9W__Y>-/M__Z]/'UR]G_/^_7<0)G_W^ M=S_\$"1^]T!A*L/]JSCYY<4_;ZZG]A*LK'.(J,>E"C-2^(X&GU]C.Y!+H?[J\OD#=1(-G4,W58WO6%3,Z28I_MB\T4[ZNLBNX=]8AE>W$YKG4'W/=G MRMDNRC8QJ7(4V,\7>'/A`,@1^HG_P9O_T_F+RZ@/_9%]]#6L?@(6D->*O%MK M!3(-%B9+-C#)9Y>D&VL1.RZ2_1F0>2;4^"C%Q9H93>2=VTOH.G'N.<&K$@#& MC<`2&3H^9:W!:Y[13FCGR/>]<\IA/W#5DFP_A1@2&?J;^> MEJFQ?^=">^AB*^L\YZ4D/FPOSDM[$/H`M)C'7:!B7BT2*B,Y$0HOX.;D,?6C MPS=DG^3U$%%*P_@0"BQ@XF2A=;IA8=BOQD4RK=%LI(06\'&R^'M&+.Y.3[>K M.^SF<)#^WC#<,\()L-X%VC]?[`EVS3ZH8T'C\ZS[Z6;0O^IUK\>34?]S;S:] MNNWU1K?3T?55OSL;]#]TK[NWO<'TTV`P.W1IHV0M)UKD*-FJ*EH_M^A=H%@^ M/5]8UCI4?>!Z-/XDVP>BC[]R3PYP_1K-AQ!9R(:LHV(*)A8A6S:._&*Y?G96M%S>A@F4:F"2,44DQ%VLPZ2;`U:/ MLE9(>M$MB M"@UIN8ZT@'HX["-O"4A*&`'X.0E-H2!/QB,MH];D\*DX>DW#+]88CQLX]=+.S5WM? M&\K&HWC:C31,#NB!:[@!SA4#$RT@+P+I&.$51`:I'O%(HI]7*;9K:,XNX[O*UBZQI:=]!E MM@Y0YN`%6^R6V&7R4.[L>=N"Z6GE[(;:>'5XCK0+L19FU98:)!G,9T]QT:'R M]L7JOIVP=&N_F%Q()/L#>&7XA&P!(@ M"C>`X8%7X!I3^@',,0%L^+L43PV5+*?U[!\`K7:S'5W'@6%KQA9DH4+/6D/F M@"046Z0/Q1G;KP`*X&FWXV4"/`LBX`PL@IBD:"Y3A#UC`$)+K=2"NR%F1NW/H?N-%># M1KN@/MWP\':RKN\M,8&_`4>)R[U,K>!P'PKM@OJ\!@<7U93A+Q=R%@YYLASF4Z.O4I:V$*8PM.WV;CSL%^5-C,*^TUKZH@:7S_::6'!Y($H=5,SSI8+Z`1L`/*!^.!Y M-E7C9ZNDB*"Y< M4$NF:!AY@;JD#O$GY6G1:LIH#8C%;\(>/*P!HJ#HJD%Q>G-ZCT1F[>9.IB!8 MG?T($&LSW\_<=580!<]*>7`#(@E$0XQ:YJ8OK2E2P=38HXB'=D/2A.'*,.&W M\O79T.GBX$(6.7_R/";15B"]=L/7GG"JYM`H5G*D%!M`VQ\UH12PF4NK& MHY2_I(1M0(1)L%,MVGW&#VPE2PFWM=P`;XF=Q#6GTHF`T[2@:0.AU#?2 M-]J;5;S@KC<'BHBBUN;SLY-5N M/?$+@(LEOZ9NPP;G!;CU5W>`C.9[BVJR7E2N#'-8+(F-=C=&"=H?*:/J\G'9 M4HSG5XR/=M=\R`[$W0)O-&>.0/B*&/N<`(N"/@A_%TV_5R_8'#VH`T7]+O>0 M235DX1=(GL[(Q:B3`S.#G*"_]R0*^>_?AAJQ3@ZFJ M6Q5BM%N*$`GZ&3&,7+X/[A-V@SM5+8BX]",T!;9/PF-'!%+V59_]BQ8AR`?J M8.7JOBLMK$Z.=HLL.5(6J)(LAZ;:4%>GRNRR$P/7S@.`>QO33G0*L*!>?3?N MZ7`>T.A=?&7=@:P#4)]3EE=R.[QX91Q;[T.=SGUJA_94PKG`$VITH&-_]P>W MTY1%[W6GGX;7HR_'&^:DM6HSR$E;V?B1=_[8ZM#%]T5;**59FKJ'&WB\+6." M-Y`Q^&'[F?+74W8;3+HLUMV$?4HNW`$%Z7/41W/%AK(GX%))FGY(]D0=)7W/=!(B[6SV(R0L;%)XT4^<_COD5@*>=H-$("IE MS6%-[6/_SIO[;OSHCGBX%F?1AFZ!WF9&;XGLVO7)QZBS#^DZ.B`]FDO?:I#G MT8:LT_7-`A"K'TG0Z.W-^*K]WS9=1!`*&CV38)H#R%P M^$P8DU(V[`L2?XJ!1@6J96!1L<#,9G&QZX, MTWH`-Y*WN92R-C^-7U)MY9Z6\9^"HU41P+ZL8P+6%G1BCS9R9+LH?%=#&DL>6%C+ ME$4-P.H!@=9:E'F6N;1?H!'UM8ER8*VWF[>I#-VCY5V`-' M?"3/.&U(A-B5P^KB=<3J56BG7>+.(U@[K`'F%AWP5=\847GOB*FZ4P:BZO&. M[IH17AA1P^XB64&&S7<=`I5V\YG,UXKL8]?^U8<$,'&8BGO;L6LA?HD(OS8D MN`%,M)RI7H!A_):!IKIOHE'`LB>XXLOVQ?E,UP#5%^G_:B;QZA:MLM%O6A64 M=?PPB_\]>(O1;?/5?0)90899C$.@TN[2"]9Z&P`GN#6,O^+`F@Z8_(4O[1;G M,XQ-!2"TN\\B:-<$K'UB+_EZ.O-3)L!C!LY)GJV1O8Y>I@3#""T%3IWW4>P? M]IE#-QZ$@M/`@)^P&SRP=J$%4[*@I:.@\NQ@6R:G(?R4`D/`BZ$+S?%*R..V M*&YMDA(/'@"Q(17>]56F!$/TX2!P!'K1X.Y@9FDB-W,TO\4>*%CP$28WC#6Q MV`**#%T>'N^D[$/N[B&G*#).IC2,U%QA!7P:NE"K[KQ7CF^:9E^BNH>%,ZT* M>`?S.;!9QX@]D`E3S1'B2#"'D?_B,W\;RP7B4QZEBC#,%)2#1Z`733ZMF=O2 M_/N?!/26*L(P>LO!(Z#WD&7YQOM]ON1=9@,)V3)S)XN:U?*V0A7V`!'H0)E9 M\$@'UH&6L682K]V:\/6RE;K`Q!)IPYM#M6&`&M^_%S^R,+:@*`K/IC*,W3TA M!2PV.+,9OVPA)2&1Q#@&DN()MI3L)A^/>/%1'U+;Q=0/[\)G(<(X4I(%,-F9W:'5C5*7RDQNM*HU],FX5I@4/AKW(H-52M%E&K!XT M=3!M;'<@NIZC>ZP7EGMP`"-KQ9`MJ$"+8,+;#=`)>[':C%IB+JJ6: M95$J8ZB#EY#<`%%#O)(L[?0!2++VION5R<8!W'GJ/H(HM6&=622SV9[!%XL0 M"WG;":N$;&KHX=D"3][)LPUXZN=5-M([ONW%B*IW>86,9O5^%21T&*T3#Z/7 M$]/'A342T\>5/W7A&FZ-30!:U'T+,IG5=8L0,'O\'EJ0!#L7;H#%_Z^IZ^<7 M>W(CD-^,)W-PL!`[0,-#HA&LSHC%I+9/2/22=:&!*%V,62:C/$HZC/U3_XZ" M7WU6P6!3CQ78*_'T$WO9%CSU_<-/5F:P+.KDXO1F]6:)W#ITVPH+BI*L8^Q" M>QO\K&5][R2M-&E'@KI4#<7N02-4S94HM7Y;%A+@;HLL6.EBFC[5).=,<1N" M`"$=;%UBH7YJ+X'CNV`TWRV\AF^S>K/@%N9:MR045M;DEH7"QC73!X/*=_HS M]=>,`(6GE0NS->7]R%$N=(94LS=L0E192SE(RM#H8D.B69SNQH(N;^(0DZGE M@L?G>.NT(:J5-3E%6MBX)QM2Q[6W8I0+S(=*3@,MAQ(@+9Q@?;28F:DB%C4D M[F453AS59)V.V#8]IGKKD>7)]M7J/QU.A;J354<=!MK3FD'6Q5TK#'3ZP&,# MR:EBOK@V/8.^N'4-62W%"2-MIHIV\`TA@I2!^A%CA]X";S2/=@")WZ4HSMFT M#2FU<5V&@';/V>Y:_063;_Q='6P#6DA5.K%1[&3DU.XIZ%U#)];]C<5\;6BY MA7RDTAI%1UI*\;-?3;/!^G$1"3R)4=@',M7W:&[FWIT&3]34YL?(B]?D?,V3 MIU)N]L@-"@=._F/!T06AH@DDM;WY?3X1?\?+/3MMAO\ MR>WV#5C=`9+!6S&3YKBKBEYC^*R`/VNU@]$'8B%[J4Z`()=I#(B$URYFWME7 MYC6!*_:G:'#(2:C]T)`GG'9S2%RGKA#S,'S>TJ%E@^Z*[U&3G`S.3:X+&WN* ME#T1G"^L#I&+TN:06M==E&O3V&_%W[YYA0%8V_+*)6O2"C^"V!CW:>M5A)=_=N1].V(Q2>FKE"CY)]PJX# MT8(+."))PN,W6=;6WAS MS,:U8J?M=Q,\/:T@&;V"M%/N#]N$]@])<#[U+)V3!I)30RETD9)D8P27ZJ2JFL[>%R'Q7M(O^$M+L_/T%`&%[+ M[378`%?-G,HRFV11I2#HRUY2Z?9%*&U>Q67HTSD5U+6P?XJATM?J7J&U[]%` MUDLU8YN3PWP:\V#0MW\F6ONR-&DOVTC:2VUW(.2U]E5ITEZUD;17U2RQZDJ`1'B]+KPL:=*J??'Q>(>O',D^H;_N+,H8)_\ M#U!+`P04````"`!`A0='D5BO9E('``!%.@``$0`<`'5T;60M,C`Q-3`V,S`N M>'-D550)``,8&,55&!C%575X"P`!!"4.```$.0$``.U;[7/:.!K_O#=S_X,N M7^C.Q!B2TFN8I#L42,H.`2;0W;V[N>D(6Q!-;8F5Y"3L7W^/9!M,;!0(=+=S MXR^MC9Z7W_.JEUB7/SV%`7H@0E+.KBKU:JV""/.X3]G\JD(E=]Z_;UPX]Y''O'1=(FZG9O6G8RH(DCRF7K$@IRBEO^`F29H\W`1*2)0 MCS'^@!5HD*?PXE5/86RQ%'1^K]";]H_HK%9[[YS5Z@WTG]'HM]:_.]>-R<^_ MW+P=_.O33>-L\M\J>GQ\K!)_CH715O5XB!Q'0Y+>/0DQ`BN8;#+.6!1>5>Z5 M6C1=5S,]3450Y6+N^DJX:KD@+A`Y0$4$]2HQWP;#X[DA!TAU][?;_MC(3PB; MD73F&"]6##,LIX8\&0"V^ENG5G?.ZRG+C`8;\B.%[T/B:Q,T=:/V[KR6TOJ$ MKF@-<$F\ZIP_N#!0(/HIH.QK$?CZQ<6%:T97I"#-5YO"$S,;;CQ800J+.5$# M'!*YP![9&78.1E;\N:N'IUB2+!9JH:=,*IU!D(D!"0E3UUR$'3+#40`6_![A M@,XH\2L(*R7H%%)L@R!B:Q+(D!\N,:2?,NFG7^%]L:!LQLW+#Y<:73.%>$=F MR/BMJ5/EZD32T%F5R>1"GTG=<&7A2!5,"LE$3P`MJVFZ6$76"18 M91#UUXI3$5AX.2FYN((0OB!"42)7_CUQCV.23V;[F@0LE-'OU:``3_4?.(L5%??.E0Z05<1H(,R&/+ M\WC$%$P_,-$P>/1,"Y`MYK?O,9L3V6-9&LH\"BZ3%M81#ZBW-/\"_A-$_:N3 MOT!O[*W$7>N"^5"#F>9=#3EHC0=>0"Y:"T:;DA%F,+W&L!!EFX0ILJ9=QBF* M\:$W*<(?+]WGV+*0(TG\(?M@GI^WL(0S(=G&M=DE=N-YEKP%3,E/:0(>/RFY M(G*$EWBJ*[,@>;+CMB#7\T'6K"CA+;U?Y/UK3,4O.(C(+<'ZW>2N7I3Y44"& ML]5P2TIBJK5/\90&5+>JA`6PWA$O$E`9\X]84CG1[BYL!-]0FRTS+G*9H34A MHPIEH311"@;Q688(5MT&D6D,&4PILX\X0RM8R.!";V)D9=D7)EZ//1"IXCG@ M`=-`^PK6F6,-CO=5J3;@>>.]W!N-L9 M3^#UMCN8#*_;K?&GZ_[PUW6P#Y1C"7K-+`C&$`13]_"L=:%$&4JUP6YZT*ZB MK$:T4HE6.M'P&FFM2*LM$V%;M3/%!=3,NMVG/R[;T#?A:?N\L0^[;2+X9V&M M)Y(WF_]*^BE*Y)<-?=<0OQ!":V7FY^H,9^GY(L^/%?>^PIJ#^/I(D#!IP%CF M3CN#;;+,K[&-+,<(0UEIY=3XNJGQ8ZO?&K2[XT_=[F2$==^Y)XH"WGWFQ>U" M;*5W_NI),=&'C$+8\695EO$O+-I?L1"8J>4=F"P>"G>^STEL,]M9KC!3;I2P MEV'8IPPS"TH8&=YV]RF_/+.M[-Z^NNPV5J"QIC+*!T7YU1WW!4FV^#>.&?^R M^1YM._+"X6LO^6 MZFQ=XNU?M/2,_+VS;9Y?!R02'>Y&N@_1_J,`N4U0M>PQZ M:_@\0+M0VQ9N\6%(PIU]U%46BT(9666DBLK(])KA;)0QN:B&BLALL'AA_NO/<^WML2SXQSAEU%]X3SAA?,":\>S?G!2>KYP MKQ5-)?D]`G.[#]O+MARP4$=U\`ZTLF\043K?Y" MJZ^_VTG]<_Y#$'`V.!1$YJ;,WD`R-TLT@,8VU85743:TY7FLUVZV@#-Z"AE= M$BB9_N*L1<6(7X!BO:9C@_*<1S]L49Y<@T%X*I7`GKJJ*!$1<"8-S,%L^F[N M$%3,]9HF4,+&H0?SK"XS@`+M`S;\D09R(WBT2`DID%10_+R`4'-_8L3XD3"H M*[J5568T^&([AV@ET.((7U5VH]TTK]B<^$Y7T^]4KREH13(E)K=J'\CFSI<^9S]E%`#[M_P9AMI+M8$^,*.8.EME@> M8$[<;U4Z-,6![KY@)IE2M;9Q^Q\Y0(N4GYD@.*!_$/\&O-N'7V`#'85Z.B)^ MP(+U&B;UQ!$%_JG^6H?_F<,\0?RLQV`WI/$,9Q/\1"18V7WRS/G"<&:.:X<+ M+6;ECYW)M;67;MS=X/%_4$L!`AX#%`````@`0(4'1QB\VS5L(@``NY(!`!$` M&````````0```*2!`````'5T;60M,C`Q-3`V,S`N>&UL550%``,8&,55=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`0(4'1SO*[H92"@``[(4``!4`&``` M`````0```*2!MR(``'5T;60M,C`Q-3`V,S!?8V%L+GAM;%54!0`#&!C%575X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`$"%!T?H!*&JRP8``+)+```5`!@` M``````$```"D@5@M``!U=&UD+3(P,34P-C,P7V1E9BYX;6Q55`4``Q@8Q55U M>`L``00E#@``!#D!``!02P$"'@,4````"`!`A0='E'SJFD,B``"+KP$`%0`8 M```````!````I(%R-```=71M9"TR,#$U,#8S,%]L86(N>&UL550%``,8&,55 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`0(4'1RDX:N.<%```[5$!`!4` M&````````0```*2!!%<``'5T;60M,C`Q-3`V,S!?<')E+GAM;%54!0`#&!C% M575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`$"%!T>16*]F4@<``$4Z```1 M`!@```````$```"D@>]K``!U=&UD+3(P,34P-C,P+GAS9%54!0`#&!C%575X C"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``", XML 17 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Current assets:

Cash $ 19,169 $ 19,274

Investments, available-for-sale 59 58

Accounts & other receivables, net 5,613 4,703

Inventories 4,473 4,872

Other current assets 662 768

Total current assets 29,976 29,675

Property and equipment, net 7,746 8,236

Goodwill 15,216 15,145

Other intangible assets 40,015 39,675

Other intangible assets - accumulated amortization (13,023) (11,655)

Other intangible assets, net 26,992 28,020

TOTAL ASSETS 79,930 81,076

Current liabilities:

Accounts payable 932 929

Accrued expenses 4,401 4,148

Current portion of notes payable 0 3,894

Total current liabilities 5,333 8,971

Notes payable 0 973

Deferred tax liability - intangible assets 5,370 5,581

Deferred income taxes 1,034 995

TOTAL LIABILITIES $ 11,737 $ 16,520

Stockholders' equity:

Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding

Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2015, 3,757 shares and December 31, 2014, 3,748 shares $ 38 $ 37

Accumulated other comprehensive income (loss) (3,408) (3,234)

Additional paid-in capital 3,029 2,890

Retained earnings 68,534 64,863

Total stockholders' equity 68,193 64,556

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 79,930 $ 81,076

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 19,169	$ 19,274
Investments, available-for-sale	59	58
Accounts & other receivables, net	5,613	4,703
Inventories	4,473	4,872
Other current assets	662	768
Total current assets	29,976	29,675
Property and equipment, net	7,746	8,236
Goodwill	15,216	15,145
Other intangible assets	40,015	39,675
Other intangible assets - accumulated amortization	(13,023)	(11,655)
Other intangible assets, net	26,992	28,020
TOTAL ASSETS	79,930	81,076
Current liabilities:
Accounts payable	932	929
Accrued expenses	4,401	4,148
Current portion of notes payable	0	3,894
Total current liabilities	5,333	8,971
Notes payable	0	973
Deferred tax liability - intangible assets	5,370	5,581
Deferred income taxes	1,034	995
TOTAL LIABILITIES	$ 11,737	$ 16,520
Stockholders' equity:
Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding
Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2015, 3,757 shares and December 31, 2014, 3,748 shares	$ 38	$ 37
Accumulated other comprehensive income (loss)	(3,408)	(3,234)
Additional paid-in capital	3,029	2,890
Retained earnings	68,534	64,863
Total stockholders' equity	68,193	64,556
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 79,930	$ 81,076

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of increase (decrease) in accumulated in equity from transactions and other events and circumstances from non-owner sources. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).
+ References
No definition available.
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

+ Details

Name: us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Trading Securities

-URI http://asc.fasb.org/extlink&oid=6526789

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 35

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Available-for-Sale Securities

-URI http://asc.fasb.org/extlink&oid=6505594

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph a, f, g

-Article 7

+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income $ 5,586 $ 5,556

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation 301 311

Amortization 1,259 1,376

Provision for (recovery of) losses on accounts receivable (9) 6

(Gain) loss on disposal of assets 1 4

Deferred income taxes (213) (282)

Stock-based compensation expense 44 24

Changes in operating assets and liabilities:

Accounts receivable (828) (1,016)

Accrued interest and other receivables (81) (31)

Inventories 218 (472)

Prepaid expenses and other current assets 104 118

Accounts payable 5 91

Accrued expenses (654) 75

Total adjustments 147 204

Net cash provided by operating activities 5,733 5,760

CASH FLOWS FROM INVESTING ACTIVITIES:

Capital expenditures for property and equipment (109) (836)

Capital expenditures for intangible assets (7) 0

Net cash provided by (used in) investing activities (116) (836)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock - options 245 271

Common stock purchased and retired (215) (818)

Payment of taxes for exchange of stock options (42) 0

Tax benefit attributable to exercise of stock options 107 120

Repayment of notes payable (4,778) (2,035)

Payment of dividends (957) (938)

Net cash provided by (used in) financing activities (5,640) (3,400)

Effect of exchange rate changes on cash (82) 20

Net increase (decrease) in cash and cash equivalents (105) 1,544

Cash at beginning of period 19,274 14,395

Cash at end of period 19,169 15,939

Cash paid during the period for income taxes 2,781 1,551

Cash paid during the period for interest $ 65 $ 167

X

- Definition
Represents the monetary amount of Payment of taxes for exchange of stock options, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_PaymentOfTaxesForExchangeOfStockOptions

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11283-113907

+ Details

Name: us-gaap_DeferredTaxExpenseFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

Notes Payable (Details)
$ in Thousands

Jun. 30, 2015

USD ($)

JP Morgan Chase Bank NA (Chase) Note

Debt Instrument, Face Amount $ 14,000

JP Morgan Chase London Branch Note

Debt Instrument, Face Amount $ 12,934

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=fil_JPMorganChaseBankNAChaseNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=fil_JPMorganChaseLondonBranchNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)
$ in Thousands

Jun. 30, 2015

USD ($)

Fair Value, Inputs, Level 1

Equities $ 59

Fair Value, Inputs, Level 2

Equities 0

Fair Value, Inputs, Level 3

Equities 0

Fair Value, Measurements, Recurring

Equities $ 59

X

- Definition
Fair value of the entity's equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_EquityFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 22 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation
6 Months Ended

Jun. 30, 2015

Notes

Basis of Presentation
(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2014. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
shares in Thousands

Jun. 30, 2015

Dec. 31, 2014

Statement of Financial Position

Preferred Stock, Par Value Per Share $ 0.01 $ 0.01

Preferred Stock, Shares Authorized 5,000 5,000

Preferred Stock, Shares Issued

Preferred Stock, Shares Outstanding

Common Stock, Par Value Per Share $ 0.01 $ 0.01

Common Stock, Shares Authorized 50,000 50,000

Common Stock, Shares Issued 3,757 3,748

Common Stock, Shares Outstanding 3,757 3,748

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

Inventories: Schedule of Inventory, Current (Tables)
6 Months Ended

Jun. 30, 2015

Tables/Schedules

Schedule of Inventory, Current

June 30, 2015

December 31, 2014

Finished goods

$

1,554

$

1,847

Work-in-process

1,101

1,103

Raw materials

1,818

1,922

Total

$

4,473

$

4,872

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document and Entity Information - USD ($)
6 Months Ended

Jun. 30, 2015

Aug. 06, 2015

Document and Entity Information:

Entity Registrant Name UTAH MEDICAL PRODUCTS INC

Document Type 10-Q

Document Period End Date Jun. 30, 2015

Amendment Flag false

Entity Central Index Key 0000706698

Current Fiscal Year End Date --12-31

Entity Common Stock, Shares Outstanding 3,758,300

Entity Public Float $ 199,695,980

Entity Filer Category Accelerated Filer

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Trading Symbol utmd

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: fil_DocumentAndEntityInformationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

Investments: Available-for-sale Securities (Tables)
6 Months Ended

Jun. 30, 2015

Tables/Schedules

Available-for-sale Securities

2Q 2015

2Q 2014

Balance, beginning of period

$

8

$

5

Realized loss from securities included in beginning balance

~

~

Gross unrealized holding gains (losses), in equity securities

4

(0)

Deferred income taxes on unrealized holding (gain) loss

(2)

0

Balance, end of period

$

10

$

5

X

- Definition
Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Income Statement

Sales, net $ 10,397 $ 10,491 $ 20,630 $ 20,318

Cost of goods sold 4,298 4,142 8,419 7,919

Gross profit 6,099 6,349 12,211 12,399

Operating expense:

Selling, general and administrative 1,992 2,172 4,071 4,256

Research & development 140 115 296 238

Total operating expense 2,132 2,287 4,367 4,494

Operating income 3,967 4,062 7,844 7,905

Other income (expense) (43) (132) (252) (193)

Income before provision for income taxes 3,924 3,930 7,592 7,712

Provision for income taxes 1,006 1,096 2,006 2,156

Net income $ 2,918 $ 2,834 $ 5,586 $ 5,556

Earnings per common share (basic) $ 0.78 $ 0.76 $ 1.49 $ 1.48

Earnings per common share (diluted) $ 0.77 $ 0.75 $ 1.48 $ 1.47

Shares outstanding (basic) 3,755 3,750 3,753 3,750

Shares outstanding (diluted) 3,773 3,775 3,775 3,778

Other comprehensive income (loss):

Foreign currency translation net of taxes of $0 in all periods $ 2,360 $ 859 $ (175) $ 1,110

Unrealized gain (loss) on investments net of taxes of $2, ($0), $0 and ($2) 2 0 1 (3)

Total comprehensive income $ 5,280 $ 3,693 $ 5,412 $ 6,663

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34747878&loc=d3e3636-108311

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Warranty Reserve
6 Months Ended

Jun. 30, 2015

Notes

Warranty Reserve
(6) Warranty Reserve. The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.”

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2014 or June 30, 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

+ Details

Name: us-gaap_ProductWarrantyDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Notes Payable
6 Months Ended

Jun. 30, 2015

Notes

Notes Payable
(5) Notes Payable. In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. and a $12,934 loan from JP Morgan Chase, London Branch to help finance UTMD’s purchase of Femcare. The notes were fully paid off in February 2015.

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

Investments: Available-for-sale Securities (Details) - USD ($)
$ in Thousands
3 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Details

Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments $ 8 $ 5

Realized loss from securities included in beginning balance

Available-for-sale Securities, Gross Unrealized Gain (Loss) $ 4 $ 0

Deferred income taxes on unrealized holding (gain) loss (2) 0

Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments $ 10 $ 5

X

- Definition
Net amount of accumulated unrealized gains (losses) on investments in available-for-sale securities impacting investments. Represents the difference between the fair value and cost of investments in available-for-sale securities.
+ References
No definition available.
+ Details

Name: fil_AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedlnlnvestments

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents the tax effects occurring during the period which are related to the net unrealized gain (loss) resulting from changes in the fair [carrying] value during the period of available-for-sale securities. Such tax affects would have been charged or credited directly to other comprehensive income or to related components of shareholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 20

-Section 45

-Paragraph 11

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=18498875&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrealized gain (loss) on investments in debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)
6 Months Ended

Jun. 30, 2015

Tables/Schedules

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

Fair Value Measurements Using

Description

Total Fair Value

at 6/30/2015

Quoted Prices

in Active Markets

for Identical Assets

(Level 1)

Significant Other

Observable Inputs

(Level 2)

Significant

Unobservable Inputs

(Level 3 )

Equities

$

59

$

59

$

0

$

0

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Events
6 Months Ended

Jun. 30, 2015

Notes

Subsequent Events
(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Investments
6 Months Ended

Jun. 30, 2015

Notes

Investments
(7) Investments. Changes in the unrealized holding gain/loss on investment securities available-for-sale and reported as a separate component of accumulated other comprehensive income are as follows:

2Q 2015

2Q 2014

Balance, beginning of period

$

8

$

5

Realized loss from securities included in beginning balance

~

~

Gross unrealized holding gains (losses), in equity securities

4

(0)

Deferred income taxes on unrealized holding (gain) loss

(2)

0

Balance, end of period

$

10

$

5

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the realized and unrealized gains and losses reported in the statement of income which have resulted from the sale and holding of marketable securities, respectively, as well as the sale or disposal of cost method investments. Such amounts would include realized gains and losses on the sale or disposal of trading, available-for-sale, and held-to-maturity securities, unrealized gains and losses on trading securities, unrealized gains and losses on available-for-sale and held-to-maturity securities transferred to the trading securities category, realized gains and losses on the sale or disposal of cost method investments, and losses recognized for other than temporary impairments (OTTI) of such investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (c)-(e)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.M)

-URI http://asc.fasb.org/extlink&oid=27011274&loc=d3e87990-122713

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

+ Details

Name: us-gaap_GainLossOnInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurements
6 Months Ended

Jun. 30, 2015

Notes

Fair Value Measurements
(8) Fair Value Measurements. The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets. The following table provides financial assets carried at fair value measured as of June 30, 2015:

Fair Value Measurements Using

Description

Total Fair Value

at 6/30/2015

Quoted Prices

in Active Markets

for Identical Assets

(Level 1)

Significant Other

Observable Inputs

(Level 2)

Significant

Unobservable Inputs

(Level 3 )

Equities

$

59

$

59

$

0

$

0

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)
6 Months Ended

Jun. 30, 2015

Policies

New Accounting Pronouncements, Policy
In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Jun. 30, 2015

Jun. 30, 2014

Details

Allocated Share-based Compensation Expense $ 22 $ 18 $ 44 $ 24

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Income Statement

Foreign currency translation tax adjustment $ 0 $ 0 $ 0 $ 0

Unrealized gain (loss) on investments tax adjustment $ 2 $ 0 $ 0 $ (2)

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e,f)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 38 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation
6 Months Ended

Jun. 30, 2015

Notes

Stock-Based Compensation
(4) Stock-Based Compensation. At June 30, 2015, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended June 30, 2015 and 2014, the Company recognized $22 and $18, respectively, in stock-based compensation cost. In the six months ended June 30, 2015 and 2014, the Company recognized $44 and $24, respectively, in stock based compensation cost.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 19 121 1 false 6 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.utahmed.com/20150630/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Sheet http://www.utahmed.com/20150630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.utahmed.com/20150630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 3 false false R4.htm 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME Sheet http://www.utahmed.com/20150630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME Statements 4 false false R5.htm 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME (Parenthetical) Sheet http://www.utahmed.com/20150630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME (Parenthetical) Statements 5 false false R6.htm 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Sheet http://www.utahmed.com/20150630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Statements 6 false false R7.htm 000070 - Disclosure - Basis of Presentation Sheet http://www.utahmed.com/20150630/role/idr_DisclosureBasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 000080 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles Sheet http://www.utahmed.com/20150630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples New Accounting Pronouncements and Changes in Accounting Principles Notes 8 false false R9.htm 000090 - Disclosure - Inventories Sheet http://www.utahmed.com/20150630/role/idr_DisclosureInventories Inventories Notes 9 false false R10.htm 000100 - Disclosure - Stock-Based Compensation Sheet http://www.utahmed.com/20150630/role/idr_DisclosureStockBasedCompensation Stock-Based Compensation Notes 10 false false R11.htm 000110 - Disclosure - Notes Payable Notes http://www.utahmed.com/20150630/role/idr_DisclosureNotesPayable Notes Payable Notes 11 false false R12.htm 000120 - Disclosure - Warranty Reserve Sheet http://www.utahmed.com/20150630/role/idr_DisclosureWarrantyReserve Warranty Reserve Notes 12 false false R13.htm 000130 - Disclosure - Investments Sheet http://www.utahmed.com/20150630/role/idr_DisclosureInvestments Investments Notes 13 false false R14.htm 000140 - Disclosure - Fair Value Measurements Sheet http://www.utahmed.com/20150630/role/idr_DisclosureFairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 000150 - Disclosure - Subsequent Events Sheet http://www.utahmed.com/20150630/role/idr_DisclosureSubsequentEvents Subsequent Events Notes 15 false false R16.htm 000160 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Sheet http://www.utahmed.com/20150630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Policies http://www.utahmed.com/20150630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples 16 false false R17.htm 000170 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) Sheet http://www.utahmed.com/20150630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables Inventories: Schedule of Inventory, Current (Tables) Tables 17 false false R18.htm 000180 - Disclosure - Investments: Available-for-sale Securities (Tables) Sheet http://www.utahmed.com/20150630/role/idr_DisclosureInvestmentsAvailableForSaleSecuritiesTables Investments: Available-for-sale Securities (Tables) Tables 18 false false R19.htm 000190 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Sheet http://www.utahmed.com/20150630/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Tables 19 false false R20.htm 000200 - Disclosure - Inventories: Schedule of Inventory, Current (Details) Sheet http://www.utahmed.com/20150630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails Inventories: Schedule of Inventory, Current (Details) Details http://www.utahmed.com/20150630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables 20 false false R21.htm 000210 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.utahmed.com/20150630/role/idr_DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.utahmed.com/20150630/role/idr_DisclosureStockBasedCompensation 21 false false R22.htm 000220 - Disclosure - Notes Payable (Details) Notes http://www.utahmed.com/20150630/role/idr_DisclosureNotesPayableDetails Notes Payable (Details) Details http://www.utahmed.com/20150630/role/idr_DisclosureNotesPayable 22 false false R23.htm 000230 - Disclosure - Investments: Available-for-sale Securities (Details) Sheet http://www.utahmed.com/20150630/role/idr_DisclosureInvestmentsAvailableForSaleSecuritiesDetails Investments: Available-for-sale Securities (Details) Details http://www.utahmed.com/20150630/role/idr_DisclosureInvestmentsAvailableForSaleSecuritiesTables 23 false false R24.htm 000240 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.utahmed.com/20150630/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details http://www.utahmed.com/20150630/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables 24 false false All Reports Book All Reports In ''UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. utmd-20150630.xml utmd-20150630_cal.xml utmd-20150630_def.xml utmd-20150630_lab.xml utmd-20150630_pre.xml utmd-20150630.xsd true true XML 40 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Inventories: Schedule of Inventory, Current (Details) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Details

Finished goods $ 1,554 $ 1,847

Work-in-process 1,101 1,103

Raw materials 1,818 1,922

Total $ 4,473 $ 4,872

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 5,586	$ 5,556
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	301	311
Amortization	1,259	1,376
Provision for (recovery of) losses on accounts receivable	(9)	6
(Gain) loss on disposal of assets	1	4
Deferred income taxes	(213)	(282)
Stock-based compensation expense	44	24
Changes in operating assets and liabilities:
Accounts receivable	(828)	(1,016)
Accrued interest and other receivables	(81)	(31)
Inventories	218	(472)
Prepaid expenses and other current assets	104	118
Accounts payable	5	91
Accrued expenses	(654)	75
Total adjustments	147	204
Net cash provided by operating activities	5,733	5,760
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for property and equipment	(109)	(836)
Capital expenditures for intangible assets	(7)	0
Net cash provided by (used in) investing activities	(116)	(836)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	245	271
Common stock purchased and retired	(215)	(818)
Payment of taxes for exchange of stock options	(42)	0
Tax benefit attributable to exercise of stock options	107	120
Repayment of notes payable	(4,778)	(2,035)
Payment of dividends	(957)	(938)
Net cash provided by (used in) financing activities	(5,640)	(3,400)
Effect of exchange rate changes on cash	(82)	20
Net increase (decrease) in cash and cash equivalents	(105)	1,544
Cash at beginning of period	19,274	14,395
Cash at end of period	19,169	15,939
Cash paid during the period for income taxes	2,781	1,551
Cash paid during the period for interest	$ 65	$ 167

Notes Payable (Details) $ in Thousands	Jun. 30, 2015 USD ($)
JP Morgan Chase Bank NA (Chase) Note
Debt Instrument, Face Amount	$ 14,000
JP Morgan Chase London Branch Note
Debt Instrument, Face Amount	$ 12,934

Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) $ in Thousands	Jun. 30, 2015 USD ($)
Fair Value, Inputs, Level 1
Equities	$ 59
Fair Value, Inputs, Level 2
Equities	0
Fair Value, Inputs, Level 3
Equities	0
Fair Value, Measurements, Recurring
Equities	$ 59

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2015
Notes
Basis of Presentation	(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2014. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares shares in Thousands	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position
Preferred Stock, Par Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	5,000	5,000
Preferred Stock, Shares Issued
Preferred Stock, Shares Outstanding
Common Stock, Par Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	50,000	50,000
Common Stock, Shares Issued	3,757	3,748
Common Stock, Shares Outstanding	3,757	3,748

Document and Entity Information - USD ($)	6 Months Ended
Document and Entity Information - USD ($)	Jun. 30, 2015	Aug. 06, 2015
Document and Entity Information:
Entity Registrant Name	UTAH MEDICAL PRODUCTS INC
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Entity Central Index Key	0000706698
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		3,758,300
Entity Public Float	$ 199,695,980
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	utmd

Notes Payable	6 Months Ended
Notes Payable	Jun. 30, 2015
Notes
Notes Payable	(5) Notes Payable. In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. and a $12,934 loan from JP Morgan Chase, London Branch to help finance UTMD’s purchase of Femcare. The notes were fully paid off in February 2015.

Investments: Available-for-sale Securities (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Details
Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments	$ 8	$ 5
Realized loss from securities included in beginning balance
Available-for-sale Securities, Gross Unrealized Gain (Loss)	$ 4	$ 0
Deferred income taxes on unrealized holding (gain) loss	(2)	0
Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments	$ 10	$ 5

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2015
Notes
Subsequent Events	(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)	6 Months Ended
	Jun. 30, 2015
Policies
New Accounting Pronouncements, Policy	In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014
Details
Allocated Share-based Compensation Expense	$ 22	$ 18	$ 44	$ 24

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2015
Notes
Stock-Based Compensation	(4) Stock-Based Compensation. At June 30, 2015, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended June 30, 2015 and 2014, the Company recognized $22 and $18, respectively, in stock-based compensation cost. In the six months ended June 30, 2015 and 2014, the Company recognized $44 and $24, respectively, in stock based compensation cost.

Inventories: Schedule of Inventory, Current (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Details
Finished goods	$ 1,554	$ 1,847
Work-in-process	1,101	1,103
Raw materials	1,818	1,922
Total	$ 4,473	$ 4,872